**PCT** WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 9/16, 15/55, C12P 13/02, 7/64, 7/62 | A1

(11) International Publication Number: WO 98/46730

(43) International Publication Date: 22 October 1998 (22.10.98)

(21) International Application Number: PCT/US98/07928

(22) International Filing Date: 16 April 1998 (16.04.98)

(30) Priority Data:
08/842,827 17 April 1997 (17.04.97) US

(71) Applicant: CELL THERAPEUTICS, INC. [US/US]; Suite 400, 201 Elliott Avenue West, Seattle, WA 98119 (US).

(72) Inventors: LEUNG, David, W.; 7625 E. Mercer Way, Mercer Island, WA 98040 (US). TOMPKINS, Christopher, K.; 17660 86th Avenue, N.E., Bothell, WA 98011 (US).

(74) Agents: BENT, Stephen, A. et al.; Foley & Lardner, Suite 500, 3000 K Street, N.W., Washington, DC 20007–5109 (US).

(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

**Published**
*With international search report.*

(54) Title: HUMAN PHOSPHATIDIC ACID PHOSPHATASE

(57) Abstract

This invention relates to a biotechnology invention concerning human phosphatidic acid phosphatase. More particularly, this invention relates to three variants of human phosphatidic acid phosphatase namely PAP–$\alpha$(1 and 2), PAP–$\beta$ and PAP–$\gamma$ and uses thereof.

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **AL** | Albania | **ES** | Spain | **LS** | Lesotho | **SI** | Slovenia |
| **AM** | Armenia | **FI** | Finland | **LT** | Lithuania | **SK** | Slovakia |
| **AT** | Austria | **FR** | France | **LU** | Luxembourg | **SN** | Senegal |
| **AU** | Australia | **GA** | Gabon | **LV** | Latvia | **SZ** | Swaziland |
| **AZ** | Azerbaijan | **GB** | United Kingdom | **MC** | Monaco | **TD** | Chad |
| **BA** | Bosnia and Herzegovina | **GE** | Georgia | **MD** | Republic of Moldova | **TG** | Togo |
| **BB** | Barbados | **GH** | Ghana | **MG** | Madagascar | **TJ** | Tajikistan |
| **BE** | Belgium | **GN** | Guinea | **MK** | The former Yugoslav Republic of Macedonia | **TM** | Turkmenistan |
| **BF** | Burkina Faso | **GR** | Greece | | | **TR** | Turkey |
| **BG** | Bulgaria | **HU** | Hungary | **ML** | Mali | **TT** | Trinidad and Tobago |
| **BJ** | Benin | **IE** | Ireland | **MN** | Mongolia | **UA** | Ukraine |
| **BR** | Brazil | **IL** | Israel | **MR** | Mauritania | **UG** | Uganda |
| **BY** | Belarus | **IS** | Iceland | **MW** | Malawi | **US** | United States of America |
| **CA** | Canada | **IT** | Italy | **MX** | Mexico | **UZ** | Uzbekistan |
| **CF** | Central African Republic | **JP** | Japan | **NE** | Niger | **VN** | Viet Nam |
| **CG** | Congo | **KE** | Kenya | **NL** | Netherlands | **YU** | Yugoslavia |
| **CH** | Switzerland | **KG** | Kyrgyzstan | **NO** | Norway | **ZW** | Zimbabwe |
| **CI** | Côte d'Ivoire | **KP** | Democratic People's Republic of Korea | **NZ** | New Zealand | | |
| **CM** | Cameroon | | | **PL** | Poland | | |
| **CN** | China | **KR** | Republic of Korea | **PT** | Portugal | | |
| **CU** | Cuba | **KZ** | Kazakstan | **RO** | Romania | | |
| **CZ** | Czech Republic | **LC** | Saint Lucia | **RU** | Russian Federation | | |
| **DE** | Germany | **LI** | Liechtenstein | **SD** | Sudan | | |
| **DK** | Denmark | **LK** | Sri Lanka | **SE** | Sweden | | |
| **EE** | Estonia | **LR** | Liberia | **SG** | Singapore | | |

# HUMAN PHOSPHATIDIC ACID PHOSPHATASE

## Field of the Invention

This invention relates to human phosphatidic acid phosphatase. More particularly, this invention relates to three variants of human phosphatidic acid phosphatase namely PAP-$\alpha$(1 and 2), PAP-$\beta$ and PAP-$\gamma$ and uses thereof. The invention encompasses biotechnology inventions, including biotechnology products and processes.

## Background of the Invention

Phosphatidic acid phosphatase (PAP) (also referred to in the art as phosphatidate phosphohydrolase) is known to be an important enzyme for glycerolipid biosynthesis. In particular, PAP catalyzes the conversion of phosphatidic acid (PA) (also referred to in the art as phosphatidate) into diacylglycerol (DAG). DAG is an important branch point intermediate just downstream of PA in the pathways for biosynthesis of glycerophosphate-based phospholipids (Kent, Anal. Rev.Biochem. 64: 315-343, 1995).

In eukaryotic cells, PA, the precursor molecule for all glycerophospholipids, is converted either to CDP-diacylglycerol (CDP-DAG) by CDP-DAG synthase (CDS) or to DAG by phosphatidic acid phosphatase (PAP). In mammalian cells, CDP-DAG is the precursor to phosphatidylinositol (PI), phosphatidylglycerol (PG), and cardiolipin (CL); whereas diacylglycerol is the precursor to triacylglycerol (TG), phosphatidylethanolamine (PE), and phosphatidylcholine (PC) in all eukaryotic cells. Therefore, the partitioning of phosphatidic acid between

CDP-diacylglycerol and diacylglycerol is an important regulatory point in eukaryotic phospholipid metabolism (Shen *et al.*, J. Biol. Chem. 271: 789-795, 1996).

In addition to being an important enzyme for glycerolipid biosynthesis, PAP is also an important enzyme for signal transduction. PAP catalyses the dephosphorylation of PA to DAG. DAG is a well-studied lipid second messenger which is essential for the activation of protein kinase C (Kent, Anal. Rev.Biochem. 64: 315-343, 1995); whereas PA itself is also a lipid messenger implicated in various signaling pathways such as NADPH oxidase activation and calcium mobilization (English, Cell Signal. 8: 341-347, 1996). The regulation of PAP activity can therefore affect the balance of divergent signaling processes that the cell receives in terms of PA and DAG (Brindley *et al.*, Chem. Phys. Lipids 80: 45-57, 1996).

Various forms of PAP have been isolated in porcine (Kai *et al.*, J. Biol. Chem. 271: 18931-18938, 1996) and rat species (Brindley *et al.*, Chem. Phys. Lipids 80: 45-57, 1996). Furthermore, the putative amino acid sequence of murine PAP has been identified. Kai *et al.*, *supra*. Prior to the instant invention, however, human PAP had not been identified or isolated.

Genes coding for PAP have been identified in *E. coli* (Dillon *et al*, J. Biol. Chem. 260: 12078-12083, 1985) and in mouse (Kai *et al.*, J. Biol. Chem. 271: 18931-18938, 1996). Furthermore, the following GenBank human cDNA clones are available: accession nos. H17855, N75714, and W70040. No uses were known, however, for these polynucleotide sequences.

Accordingly, there is a need for the identification and isolation of human PAP and for methods of using human

PAP, for example, for the dephosphorylation of a substrate.

## Summary of the Invention

It is therefore an object of the present invention to provide a polynucleotide sequences encoding three or more variants of human PAP, namely PAP-α(1 and 2), PAP-β and PAP-γ.

It is a further object to provide the isolated protein of these three variants.

It is yet a further object to provide a biotechnology method for preparing these variants via recombinant methods.

It is a further object to provide a biotechnology method of using these variants or human PA in general to synthesize DAG.

In accomplishing these and other objects there is provided an isolated polynucleotide encoding human phosphatidic acid phosphatase wherein the polynucleotide encodes a protein comprising a polypeptide sequence selected from the group consisting of (i) the sequence at amino acid number 1 to amino acid number 284 (SEQ ID NO:2) in Figure 1, (ii) the sequence at amino acid number 1 to amino acid number 285 (SEQ ID NO:4) in Figure 2, and (iii) the sequence at amino acid number 1 to amino acid number 276 (SEQ ID NO:8) in Figure 4.

There is further provided an isolated human phosphatidic acid phosphatase protein, wherein the protein comprises a polypeptide sequence selected from the group consisting of (i) the sequence at amino acid number 1 to amino acid number 284 (SEQ ID NO:2) in Figure 1, (ii) the sequence at amino acid number 1 to amino acid number 285 (SEQ ID NO:4) in Figure 2, and (iii) the sequence at amino acid number 1 to amino acid number 276 (SEQ ID NO:8) in Figure 4.

There if further provided a method of preparing a human phosphatidic acid phosphatase-β protein comprising the steps of (i) transforming a host cell with an expression vector comprising a polynucleotide encoding human phosphatidic acid phosphatase, (ii) culturing the transformed host cells which express the protein and (iii) isolating the protein.

There if further provided a method of dephosphorylating a substrate comprising contacting the substrate with an effective amount of isolated human phosphatidic acid phosphatase protein such that the protein catalyzes the dephosphorylation of the substrate. It is further provided that the substrate of this method is selected from the group consisting of phosphatidic acid, lysophosphatidic acid, ceramide 1-phosphate, and sphingosine 1-phosphate. It is further provided that this method occurs *in vitro*, and comprises a step of isolating the dephosphoryled substrate. Additionally, the method can occur *in vivo*, and is effected by the administration of human phosphatidic acid phosphatase to a mammal in need thereof.

## Brief Description of the Drawings

Figure 1 shows the DNA sequence of the cDNA insert of the human PAP-α1 isolated herein and the corresponding amino acid sequence (SEQ ID NOS:1 and 2).

Figure 2 shows the DNA sequence of the cDNA insert of the human PAP-α2 isolated herein and the corresponding amino acid sequence (SEQ ID NOS:3 and 4).

Figure 3 shows the DNA sequence of the cDNA insert of the human PAP-β isolated herein and the corresponding amino acid sequence (SEQ ID NOS:5 and 6).

Figure 4 shows the DNA sequence of the cDNA insert of the human PAP-γ isolated herein and the corresponding amino acid sequence (SEQ ID NOS:7 and 8).

Figure 5 shows amino acid sequences alignment of the murine PAP coding sequence and the coding sequences for human PAP-α(1 and 2), PAP-β and PAP-γ (SEQ ID NOS:9-13).

Figure 6 shows the effect of IL-1β on PAP-β expression in human endothelial ECV304 cells using Northern blot analysis.

Figure 7 depicts a thin layer chromatography analysis demonstrating the increase in PA dephosphorylation in cells transfected with either the PAP-α1 or PAP-α2 cDNA expression plasmids.

Figure 8 shows the differential expression of PAP-α mRNA in various tumor versus normal tissues.

Figure 9 is a schematic representation of glycerophospholipid biosynthesis involving the conversion of PA to either DAG or CDP-DAG. The synthesis of PA to DAG involves the PAP enzyme, while the synthesis of PA to CPD-DAG involves the CDS enzyme.

## Detailed Description of Preferred Embodiments

This invention relates to isolated human phosphatidic acid phosphatase. More particularly, this invention relates to three variants of human phosphatidic acid phosphatase namely PAP-α(1 and 2), PAP-β and PAP-γ.

Examples of the uses for human PAP include the following. PAP is an important tool for enzymatic catalysis of several biologically significant proteins. As discussed above, PAP catalyzes the dephosphorylation of PA to DAG. DAG, in turn, is essential for the activation of protein kinase C (Kent, Anal. Rev.Biochem. 64: 315-343, 1995).

Moreover, PAP catalyzes the dephosphorylation of lysophosphatidic acid (LPA), ceramide 1-phosphate (C-1-P), and sphingosine 1-phosphate (S-1-P) (Brindley et al., *Chem. Phys. Lipids* 80: 45-57, 1996). In the case of LPA, S-1-P, and C-1-P, the products of the PAP reaction are monoacylglycerol, sphingosine, and ceramide,

respectively. PAP can control the balance of a wide spectrum of lipid mediators of cell activation and signal transduction by modulating the phosphorylated state of these lipids.

Additionally, the human PAP of the present invention are likely to define a new family of tumor suppressor genes that can be used as candidate genes for gene therapy for the treatment of certain tumors. The relationship of PAP and tumor suppression is evidenced in findings that PAP activity is lower in fibroblast cell lines transformed with either the *ras* or *fps* oncogene than in the parental rat1 cell line (Brindley *et al.*, *Chem. Phys. Lipids* 80: 45-57, 1996). Decrease in PAP activity in transformed cells correlates with a concomitant increase in PA concentration. Moreover, elevated PAP activity and lower level of PA has been observed in contact-inhibited fibroblasts relative to proliferating and transformed fibroblasts (Brindley *et al.*, *Chem. Phys. Lipids* 80: 45-57, 1996). Therefore, PAP plays a role in decreasing cell division and as such can provide a useful tool in treating cancer.

Additionally, PA, the substrate for the enzyme PAP, has been implicated in cytokine induced inflammatory responses (Bursten *et al.*, Circ. Shock 44: 14-29, 1994; Abraham *et al.*, J. Exp. Med. 181: 569-575, 1995; Rice *et al.*, Proc. Natl. Acad. Sci. USA 91: 3857-3861 1994; Leung *et al.*, Proc. Natl. Acad. Sci. USA 92: 4813-4817, 1995) and the modulation of numerous protein kinases involved in signal transduction (English *et al.*, Chem. Phys. Lipids 80: 117-132, 1996). Because of the possibility that activation of human PAP expression can counter-balance the inflammatory response from cytokine stimulation through degradation of excess amount of PA in cells, the genes encoding human PAP can be used in gene therapy for the treatment of inflammatory diseases.

Human PAP described herein can also be used in gene therapy for the treatment of obesity associated with diabetes. PAP activity is decreased in the livers and hearts of the grossly obese and insulin resistant JCR:LA corpulent rat compared to the control lean phenotype (Brindley *et al.*, *Chem. Phys. Lipids* 80: 45-57, 1996). Human PAP described herein therefore can provide an important tool for the treatment of obesity associated with diabetes.

**1. Human PAP**

As used herein, "phosphatidic acid phosphatase" or "PAP" refers to a protein capable of catalyzing the dephosphorylation of PA to DAG. PAP also includes proteins capable of catalyzing the dephosphorylation of lysophosphatidic acid (LPA), ceramide 1-phosphate (C-1-P), and sphingosine 1-phosphate (S-1-P).

As used herein, "isolated" PAP denotes a degree of separation of the protein from other materials endogenous to the host organism. As used herein, "purified" denotes a higher degree of separation than isolated. A purified protein is sufficiently free of other materials endogenous to the host organism such that any remaining materials do not adversely affect the biological properties of the protein, for example, a purified protein is one sufficiently pure to be used in a pharmaceutical context.

As used herein, "human" PAP refers to PAP naturally occurring (or "native") in the human species, including natural variations due to allelic differences. The term "human PAP," however, is not limited to native human proteins, but also includes amino acid sequence variants of native human PAP that demonstrate PAP activity, as defined above.

Variants often exhibit the same qualitative biological activity as the naturally-occurring analogue,

although variants also are selected in order to modify the characteristics of PAP protein. In a preferred embodiment, therefore, human PAP includes the amino acid sequences of Figures 1-4 (SEQ ID NOS:2, 4, 6 and 8), being PAP-α1, PAP-α2, PAP-β and PAP-γ, respectively and variants thereof.

Amino acid sequence variants of the protein can be substitutional, insertional or deletion variants. Deletion variants lack one or more residues of the native protein which are not essential for biological activity. An example of a common deletion variant is a protein lacking transmembrane sequences. Another example is a protein lacking secretory signal sequences or signal sequences directing the protein to bind to a particular part of a cell.

Substitutional variants typically contain the exchange of one amino acid for another at one or more sites within the protein, and are designed to modulate one or more properties of the protein such as stability against proteolytic cleavage. Substitutions preferably are conservative, that is, one amino acid is replaced with one of similar shape and charge. Conservative substitutions are well known in the art and include, for example, the changes of: alanine to serine; arginine to lysine; asparigine to glutamine or histidine; aspartate to glutamate; cysteine to serine; glutamine to asparigine; glutamate to aspartate; glycine to proline; histidine to asparigine or glutamine; isoleucine to leucine or valine; leucine to valine or isoleucine; lysine to arginine, glutamine, or glutamate; methionine to leucine or isoleucine; phenylalanine to tyrosine, leucine or methionine; serine to threonine; threonine to serine; tryptophan to tyrosine; tyrosine to tryptophan or phenylalanine; and valine to isoleucine or leucine. Of course, other amino acid substitutions can be undertaken.

Insertional variants contain fusion proteins such as those used to allow rapid purification of the protein and also can include hybrid proteins containing sequences from other proteins and polypeptides which are protein homologues.

Variants of human PAP also include fragments, analogs, derivatives, muteins and mimetics of the natural PAP protein that retain the ability to cause the beneficial results described above. Fragments of the human PAP protein refer to portions of the amino acid sequence of the PAP polypeptide that also retain this ability.

Variants can be generated directly from the human PAP protein itself by chemical modification by proteolytic enzyme digestion, or by combinations thereof. Additionally, methods of synthesizing polypeptides directly from amino acid residues also exist.

Non-peptide compounds that mimic the binding and function of the human PAP protein ("mimetics") can be produced by the approach outlined in Saragovi *et al.*, *Science* 253: 792-95 (1991). Mimetics are peptide-containing molecules which mimic elements of protein secondary structure. See, for example, Johnson *et al.*,"Peptide Turn Mimetics" in BIOTECHNOLOGY AND PHARMACY, Pezzuto *et al.*, Eds., (Chapman and Hall, New York, 1993).

The underlying rationale behind the use of peptide mimetics is that the peptide backbone of proteins exists chiefly to orient amino acid side chains in such a way as to facilitate molecular interactions For the purposes of the present invention, appropriate mimetics can be considered to be the equivalent of the human PAP protein itself.

More typically, at least in the case of gene therapy, variants are created by recombinant techniques employing genomic or cDNA cloning methods. Site-specific

and region-directed mutagenesis techniques can be employed. See CURRENT PROTOCOLS IN MOLECULAR BIOLOGY vol. 1, ch. 8 (Ausubel *et al.* eds., J. Wiley & Sons 1989 & Supp. 1990-93); PROTEIN ENGINEERING (Oxender & Fox eds., A. Liss, Inc. 1987). In addition, linker-scanning and PCR-mediated techniques can be employed for mutagenesis. See PCR TECHNOLOGY (Erlich ed., Stockton Press 1989); CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, vols. 1 & 2, *supra*. Protein sequencing, structure and modeling approaches for use with any of the above techniques are disclosed in PROTEIN ENGINEERING, *loc. cit.* and CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, vols. 1 & 2, *supra*.

**2. Polynucleotides Encoding Human PAP**

The present invention further includes isolated polynucleotides encoding human phosphatidic acid phosphatase. As used herein, an "isolated" polynucleotide denotes a degree of separation of the polynucleotide from its naturally occurring environment, *e.g.*, from its native intact genome. In a preferred embodiment, the isolated polynucleotides correspond to those shown in Figure 1 at nucleotide number 342 to nucleotide number 1193 of SEQ ID NO:1; Figure 2 at nucleotide number 342 to nucleotide number 1196 of SEQ ID NO:3; Figure 3 at nucleotide number 294 to nucleotide number 1226 of SEQ ID NO:5; and Figure 4 at nucleotide number 4 to nucleotide number 833 of SEQ ID NO:7.

The invention furthermore relates to a polynucleotide whose sequence is degenerate with respect to the sequences mentioned above in accordance with the nature of the genetic code. Degeneracy is often referred to as codon/anticodon wobble, and is discussed in Watson *et al.*, MOLECULAR BIOLOGY OF THE GENE (4th ed. 1987) at 437-43.

The present invention further includes bases, nucleosides, nucleotides, oligonucleotides derived from the isolated polynucleotides of the present invention. The term "derived" when used in the context of the present invention connotes a degree of similarity that is sufficient to indicate the original polynucleotide from which hybrid forms, or portions thereof, were obtained. Also within the scope of the invention are so-called "polyamide" or "peptide" nucleic acids ("PNAs") derived from the polynucleotides of the present invention. PNAs are constructed by replacing the (deoxy)ribose phosphate backbone of a subject polynucleotide with an achiral polyamide backbone or the like. See Nielsen *et al.*, *Science* 254: 1497-54 (1991).

The above polynucleotides and derivations thereof can be used as important tools in recombinant DNA and other protocols involving nucleic acid hybridization techniques. More specifically, oligonucleotides and nucleic acids derived from the isolated polynucleotides shown in Figures 1-4 (SEQ ID NOS:1, 3, 5, and 7) can be used as hybridization probes, capable of recognizing and specifically binding to complementary nucleic acid sequences, providing thereby a means of detecting, identifying, locating and measuring complementary nucleic acid sequences in a biological sample.

Biological samples include, among a great many others, blood or blood serum, lymph, ascites fluid, urine, microorganism or tissue culture medium, cell extracts, or the like, derived from a biological source, or a solution containing chemically synthesized protein, or an extract or solution prepared from such fluid from a biological source.

An oligonucleotide containing a modified nucleotide of the invention can be used as a primer to initiate nucleic acid synthesis at locations in a DNA or RNA molecule comprising the sequence complementary to the

oligonucleotide sequence. The synthesized nucleic acid strand would have incorporated, at its 5' terminus, the oligonucleotide primer bearing the invention and would, therefore, be detectable by exploitation of the characteristics of the detectable label. Two such primers, specific for different nucleotide sequences on complementary strands of dsDNA, can be used in the polymerase chain reaction (PCR) to synthesize and amplify the amount of a nucleotide sequence. The detectable label present on the primers will facilitate the identification of desired PCR products. PCR, combined with techniques for preparing complementary DNA (cDNA) can be used to amplify various RNAs, with oligonucleotide primers again serving both to provide points for initiation of synthesis in the cDNA duplex flanking the desired sequence and to identify the desired product. Primers labeled with the invention may also be utilized for enzymatic nucleic acid sequencing by the dideoxy chain-termination technique.

The invention can be applied to measure or quantitate the amount of DNA present in a sample. For instance, the concentration of nucleic acid can be measured by comparing detectable labels incorporated into the unknown nucleic acid with the concentration of detectable labels incorporated into known amounts of nucleic acid.

Such a comparative assessment can be done using biotin where the respective concentrations are determined by an enzyme-linked assay utilizing the streptavidin-alkaline phosphatase conjugate and a substrate yielding a soluble chromogenic or chemiluminescent signal.

### 3. Recombinant Production of Human PAP

In a further embodiment human PAP is expressed via recombinant methods known to those of skill in the art. The polynucleotides of the present invention can be

expressed in any number of different recombinant DNA expression systems to generate large amounts of protein, which can then be purified and used for the various applications of human PAP described above. Included within the present invention are proteins having native glycosylation sequences, and deglycosylated or unglycosylated proteins prepared by the methods described below.

Recombinant technology for producing desired proteins is known by ordinarily skilled artisans and includes providing a coding sequence for a desired protein, and operably linking the coding sequence to polynucleotide sequences capable of effecting its expression.

With regard to one aspect of the invention, it often is desirable to produce human PAP as a fusion protein, freed from upstream, downstream or intermediate sequences, or as a protein linked to leader sequences, effecting secretion of human PAP into cell culture medium.

A typical expression system will also contain control sequences necessary for transcription and translation of a message. Known control sequences include constitutive or inducible promoter systems, translational initiation signals (in eucaryotic expression), polyadenylation translation termination sites, and transcription terminating sequences. Expression vectors containing controls which permit operably linking of desired coding sequences to required control systems are known by the skilled artisan. Such vectors can be found which are operable in a variety of hosts.

Human PAP of the present invention may be produced in procaryotic cells using appropriate controls, such as *trp* or *lac* promoters, or in eucaryotic host cells, capable of effecting post-translational processing that

permits proteins to assume desired three-dimensional conformation. Eucaryotic control systems and expression vectors are known; including *leu* and glycolytic promoters useful in yeast, the viral SV40 and adenovirus and CMV promoters in mammalian cells, and the baculovirus system which is operable in insect cells. Plant vectors with suitable promoters, such as the *nos* promoter are also available.

Standard laboratory manuals (*e.g.*, Sambrook *et al.*, MOLECULAR CLONING: A LABORATORY MANUAL, Second Edition, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 1989) present standard techniques and methodologies for expressing polynucleotides encoding a desired protein, culturing appropriate cells, providing suitable expression conditions, and recovering a resulting protein from culture.

In preparing the inventive human PAP, a suitable polynucleotide encoding human PAP, constructed utilizing any of the foregoing techniques is operable linked to an expression vector which is then transformed into a compatible host. Host cells are cultured using conditions appropriate for growth. Expression of the desired human PAP is preferably induced after some predetermined growth level has occurred. Human PAP production is monitored and the desired protein isolated from culture either from a supernatant, or by first lysing host cells with an appropriate agent, or by other methods known to the skilled artisan.

In another preferred embodiment, a polynucleotide encoding human PAP is ligated into a mammalian expression vector. A preferred mammalian expression vector is the plasmid "pCE2." The plasmid pCE2 is derived from pREP7b (Leung, et al., Proc. Natl. Acad. Sci. USA, 92: 4813-4817, 1995) with the RSV promoter region replaced by the CMV enhancer and the elongation factor-1α (EF-1α) promoter and intron. The CMV enhancer of the pCE2 vector

is constructed from a 380 bp Xba I-Sph I fragment produced by PCR from pCEP4 (Invitrogen, San Diego, CA) using the primers 5'-GGCTCTAGAT ATTAATAGTA ATCAATTAC-3' (SEQ ID NO:14) and 5'-CCTCACGCAT GCACCATGGT AATAGC-3' (SEQ ID NO:15). The EF-1α promoter and intron (Uetsuki, et al., J. Biol. Chem., 264: 5791-5798, 1989) are constructed from a 1200 bp Sph I-Asp718 I fragment produced by PCR from human genomic DNA using the primers 5'-GGTGCATGCG TGAGGCTCCG GTGC-3' (SEQ ID NO:16) and 5'-GTAGTTTTCA CGGTACCTGA AATGGAAG-3' (SEQ ID NO:17). These 2 fragments are ligated into a Xba I/Asp718 I digested vector derived from pREP7b to generate pCE2.

In another preferred embodiment of the present invention, pCE2 containing a polynucleotide expressing human PAP is used to transform a host cell which then expresses the protein. Preferred host cells include the human embryonic kidney cell line 293-EBNA (Invitrogen, San Diego, CA), endothelial ECV304 cells, and epithelial A549 cells.

**4. Dephosphorylation of Substrate**

In another embodiment, the present invention includes a method of dephosphorylating a substrate by contacting the substrate with an effective amount of isolated human PAP. An "effective amount" of human PAP is an amount which will dephosphorylate a detectable amount of substrate. Such an amount can be determined empirically based on variables well known to those of skill in the art, such as reaction time and temperature.

In one embodiment, the substrate includes phosphatidic acid, lysophosphatidic acid, ceramide 1-phosphate, and sphingosine 1-phosphate. In another embodiment, the isolated human PAP includes PAP-α(1 and 2), PAP-β and PAP-γ and variants thereof.

In a further embodiment, the dephosphorylation of substrate occurs *in vitro*, by contacting a substrate with

recombinantly produced human PAP expressed by the methods described above. The dephosphorylated substrate is then isolated by standard isolation and purification methods, including for example, thin layer chromatography or high pressure liquid chromatography.

In another embodiment, the dephosphorylation of substrate occurs *in vivo* via the administration of human PAP to a mammal, preferably a human. "Administration" means delivery of human PAP protein to a mammal by methods known to those of skill in the art including, but not limited to: orally, for example in the form of pills, tablets, lacquer tablets, coated tablets, granules, hard gelatin capsules, soft gelatin capsules, solutions, syrups, emulsions, suspensions or aerosol mixtures; rectally, for example in the form of suppositories; parenterally, for example in the form of injection solutions or infusion solutions, microcapsules or rods; percutaneously, for example in the form of ointments or tinctures; transdermally; intravascularly, intracavitarily; intramuscularly; subcutaneously; and nasally, for example in the form of nasal sprays or inhalants.

The administration of human PAP protein includes the administration of the protein combined in a mixture with a pharmaceutically acceptable carrier vehicle. Suitable vehicles and their formulation, inclusive of other human proteins, e.g. human serum albumin, are described for example in Remington's *Pharmaceutical Sciences* by E.W. Martin, which is hereby incorporated by reference. Such compositions will contain an effective amount of protein hereof together with a suitable amount of vehicle in order to prepare pharmaceutically acceptable compositions suitable for effective administration to the host.

Such compositions should be stable for appropriate periods of time, preferably are acceptable for administration to humans and preferably are readily

manufacturable. Although pharmaceutical solution formulations are provided in liquid form appropriate for immediate use, formulations may also be provided in frozen or in lyophilized form. In the former case, the composition must be thawed prior to use. The latter form is often used to enhance the stability of the medicinal agent contained in the composition under a wide variety of storage conditions. Such lyophilized preparations are reconstituted prior to use by the addition of suitable pharmaceutically acceptable diluents, such as sterile water or sterile physiological saline solution.

Additionally, administration is meant to include delivery of human PAP protein to a mammal by means of gene therapy techniques, *i.e.*, by the delivery of polynucleotides encoding human PAP to PAP-deficient cells, whereby human PAP is then expressed in the cell. Gene therapy techniques are known to those of skill in the art. For example, listing of present-day vectors suitable for use in gene therapy of the present invention is set forth in Hodgson, *Bio/Technology* 13: 222 (1995). *See also*, Culver *et al.*, *Science*, 256:1550-62 (1992).

Additionally, liposome-mediated gene transfer is another suitable method for the introduction of a recombinant vector containing a polynucleotide encoding human PAP into a PAP-deficient cell. *See* Caplen *et al.*, *Nature Med.* 1:39-46 (1995) and Zhu *et al.*, *Science* 261:209-211 (1993).

Additionally, viral vector-mediated gene transfer is also a suitable method for the introduction of a recombinant vector containing the gene encoding human PAP into a PAP-deficient cell. Examples of appropriate viral vectors are adenovirus vectors. Detailed discussions of the use of adenoviral vectors for gene therapy can be found in Berkner, *Biotechniques* 6:616-629 (1988), Trapnell, *Advanced Drug Delivery Rev.* 12:185-199 (1993).

The following examples merely illustrate the invention and, as such, are not to be considered as limiting the invention set forth in the claims.

## Example 1
## Cloning and Expression of Human PAP-α, PAP-β and PAP-γ

Homology search of the Genbank database (Boguski, et al., Science 265:1993-1994, 1994) of expressed sequence tag (dbEST) using the murine PAP protein sequence (Kai *et al.*, J. Biol. Chem. 271: 18931-18938, 1996) as probe identified several short stretches of human cDNA sequences with homology to the murine PAP protein sequence. These cDNA sequences of interest were derived from single-run partial sequencing of random human cDNA cloning projects carried out mainly by I.M.A.G.E. Consortium [LLNL] cDNA clones program. Based on the partial DNA sequences available in the GenBank database, the human cDNA clones that are homologous to the murine PAP protein sequence can be grouped into three classes, suggesting the presence of at least three different human PAP variants, designated as PAP-α, PAP-β, and PAP-γ here. For instance, a potential human PAP-α clone (GenBank #H17855) identified contains sequence homologous to aa 272-283 and the 3'-untranslated region of murine PAP; a potential human PAP-β clone (GenBank #W70040) identified contains sequence similarities corresponding to aa 175-251 of murine PAP; and a potential human PAP-γ clone (GenBank #N75714) identified contains sequences similarities corresponding to aa 18-142 of murine PAP. These cDNA clones were purchased (Genome Systems, St. Louis, MO) for further analysis. DNA sequence determination of the entire cDNA inserts of these clones showed clone H17855 contained sequences that are homologous to the N- and C-terminal sequences of murine PAP with a gap of about 150 bp that led to a frame shift in reading frame. This clone is most likely a

spuriously spliced form of PAP-α clone. Clone W70040 was found to be a full-length PAP-β clone, and clone N75714 was found to be a partial PAP-γ clone with an open reading frame homologous to the region from aa18 to the C-terminus of murine PAP.

To assemble a full-length functional PAP-α clone, synthetic oligonucleotides o_papa1F, 5'-ggcatggtAC CATGTTTGAC AAGACGCGGC-3' (SEQ ID NO:18), based on the N-terminal region of PAP-α and o_papa1R, 5'-CATATGTAGT ATTCAATGTA ACC-3' (SEQ ID NO:19), based on a region downstream of a Pst I site complementary to the coding strand of PAP-α were used to amplify the N-terminal coding region of PAP-α from a human lung cDNA library (Life Technologies, Inc., Gaithersburg, MD). The 450 bp Acc65 I - Pst I fragment generated was inserted into a Acc65 I / Pst I vector from pBluescript(II)SK(-) (Stratagene, San Diego, CA) for further analysis. DNA sequence analysis of the subclones obtained revealed at least two different classes of clones with sequences that diverged at the putative exon of interest, suggesting the presence of two alternatively spliced forms of PAP-α. These two alternatively spliced forms of PAP-α are designated as PAP-α1 and PAP-α2 here. Each of the individual 450 bp Acc65 I - Pst I fragment generated by PCR was combined with the 810 bp Pst I - Not I fragment derived from clone H17855 for ligation into a Acc65 I / Not I mammalian expression vector derived from pCE2 for the generation of expression plasmids for PAP-α1 and PAP-α2. The plasmid pCE2 was derived from pREP7b (Leung, et al., Proc. Natl. Acad. Sci. USA, 92: 4813-4817, 1995) with the RSV promoter region replaced by the CMV enhancer and the elongation factor-1α (EF-1α) promoter and intron. The CMV enhancer of the pCE2 vector was constructed from a 380 bp Xba I-Sph I fragment produced by PCR from pCEP4 (Invitrogen, San Diego, CA) using the primers 5'-GGCTCTAGAT ATTAATAGTA ATCAATTAC-3' (SEQ ID NO:14) and 5'-

CCTCACGCAT GCACCATGGT AATAGC-3' (SEQ ID NO:15). The EF-1α promoter and intron (Uetsuki, et al., J. Biol. Chem., 264: 5791-5798, 1989) was constructed from a 1200 bp Sph I-Asp718 I fragment produced by PCR from human genomic DNA using the primers 5'-GGTGCATGCG TGAGGCTCCG GTGC-3' (SEQ ID NO:16) and 5'-GTAGTTTTCA CGGTACCTGA AATGGAAG-3' (SEQ ID NO:17). These 2 fragments were ligated into a Xba I/Asp718 I digested vector derived from pREP7b to generate pCE2.

The DNA sequence determined from clone N75714 was used as a probe to search for clones with overlapping sequences in the GenBank database. Clone Z43618 was found to contain an additional 5'-sequence with a potential ATG initiation codon. To assemble a full-length PAP-γ clone, synthetic oligonucleotides o_papg1F, 5'-tgatggctag cATGCAGAGA AGATGGGTCT TCGTGCTGCT CGACGTG-3' (SEQ ID NO:20), based on the N-terminal region of PAP-γ and o_papg1R, 5'-AGTGCGGGAT CCCATAAGTG GTTG-3', (SEQ ID NO:21) based on a region complementary to the coding strand of PAP-γ just downstream of its stop codon were used to generate the full-length coding region of PAP-γ by PCR using the clone N75714 as template. The 820 bp Nhe I - BamH I fragment obtained was then ligated into a Nhe I / BamH I mammalian expression vector derived from pCE2.

Figures 1, 2, 3 and 4 show the translated DNA sequences of the putative human cDNA clones for PAP-α1, α2, β and γ, (SEQ ID NOS:1, 3, 5 and 7) respectively. The designated ATG initiation site for translation of each cDNA clone fulfills the requirement for an adequate initiation site according to Kozak (Kozak, Critical Rev. Biochem. Mol. Biol. 27:385-402, 1992).

The amino acid sequence of each open reading frame (Figures 1, 2, 3 and 4 (SEQ ID NOS:2, 4, 6 and 8)) was used as the query sequence to search for homologous sequences in protein databases. Search of the Genbank

database from the National Center for Biotechnology Information (NCBI) using the blastp program showed that these proteins are most homologous to the murine PAP sequence (Kai *et al.*, J. Biol. Chem. 271: 18931-18938, 1996), and a rat endoplasmic reticulum resident transmembrane protein of unknown function, *Dri 42*, whose expression is up-regulated during epithelial differentiation (Barila *et al.*, J. Biol. Chem. 271: 29928-29936, 1996).

## Example 2
## Activation of PAP-β Transcription by IL1-β

It is possible that activation of PAP-β expression can counter-balance the inflammatory response from IL-1β stimulation through degradation of the excess amount of PA in cells. To determine whether IL1-β, an inflammatory cytokine, would activate the transcription of PAP mRNAs, Northern analysis of PAP-β mRNA levels (Fig. 6) was performed in human endothelial ECV304 cells at various times after IL-1β stimulation. Figure 6 shows that PAP-β mRNA expression was induced after incubation of ECV304 cells with IL-1β after at least 6 hours, suggesting that PAP-β is a late-response gene to IL-1β stimulation. This indicates that human PAP may act to reduce IL-1β induced inflammation by degrading excess PA in cells.

## Example 3
## PAP-α1 and PAP-α2 Dephosphorylation of PA to DAG

The expression of PAP-α1 and PAP-α2 cDNA was found to increase PA dephosphorylation in mammalian cells. The expression plasmids for PAP-α1, PAP-α2 and the control vector were transiently transfected into 293-EBNA (EB293) cells (Invitrogen, San Diego, CA) using the lipofectant DOTAP (Boehringer Mannheim, Indianapolis, IN). PAP activities were followed by TLC analysis based on the conversion of [$C^{14}$]PA (DuPont NEN, Boston, MA) to

[$C^{14}$]DAG using membrane fractions isolated from the various cell extracts. Figure 7 shows membrane fractions derived from cells transfected with either the PAP-α1 (lanes 6 and 7) or PAP-α2 (lanes 8 and 9) produced more [$C^{14}$]DAG those from untransfected cells (lanes 2 and 3) or from cells transfected with the control pCE2 vector (lanes 4 and 5). In this particular chromatography system, DAG can be resolved into two bands, possibly due to heterogeneity in the acyl-chains. It appears that PAP-α1 and PAP-α2 preferentially dephosphorylate different species of PA as evidenced by the change in relative intensity of the two DAG bands (lanes 6 to 9).

## Example 4
## Differential Expression of PAP-α mRNA in Selected Tumor Versus Normal Tissues

The possibility that PAP-α expression can degrade the excess amount of PA in cells suggests that PAP-α may be down-regulated in tumor cells when compared to normal cells, as tumor cells tend to be more inflammatory due to a possibly higher level of PA when compared to normal or resting cells. To test this hypothesis, Northern analysis using PAP-α(1 and 2) cDNA probe was performed on RNA blots derived from various matching pairs of tumor and normal tissues (Invitrogen, Carlsbad, CA). Figure 8 shows the expression levels of PAP-α mRNA are substantially higher in five out of eight of the normal tissues examined; namely, colon, rectal, breast, fallopian tube, and ovarian tissues when compared to the corresponding tumor tissues.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: LEUNG, David W.
TOMPKINS, Christopher K.

(ii) TITLE OF INVENTION: HUMAN PHOSPHATIDIC ACID PHOSPHATASE

(iii) NUMBER OF SEQUENCES: 21

(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Foley & Lardner
(B) STREET: 3000 K Street, N.W., Suite 500
(C) CITY: Washington
(D) STATE: D.C.
(E) COUNTRY: USA
(F) ZIP: 20007-5109

(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30

(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: US 08/842,827
(B) FILING DATE: 17-APR-1997
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: BENT, Stephen A.
(B) REGISTRATION NUMBER: 29,768
(C) REFERENCE/DOCKET NUMBER: 77319/125

(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (202)672-5300
(B) TELEFAX: (202)672-5399
(C) TELEX: 904136

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1563 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 342..1193

(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 342..1193

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CCTGTGGGAG AGAGCGCCGG GATCCGGACG GGGTAGCAAC CGGGGCAGGC CGTGCCGGCT 60

GAGGAGGTCC TGAGGCTACA GAGCTGCCGC GGCTGGCACA CGAGCGCCTC GGCACTAACC 120

```
GAGTGTTCGC GGGGGCTGTG AGGGGAGGGC CCCGGGCGCC ATTGCTGGCG GTGGGAGCGC      180

CGCCCGGTCT CAGCCCGCCC TCGGCTGCTC TCCTCCTCCG GCTGGGAGGG GCCGTATCTC      240

GGGGCCGTCG CCAGCCCCGG CCCGGGCTCG ATAATCAAGG GCCTCGGCCG TCGTCCCGCA      300

CCTCATTCCA TCGCCCTTGC CGGGCAGCCC GGGCAGAGAC C ATG TTT GAC AAG           353
                                               Met Phe Asp Lys
                                                 1

ACG CGG CTG CCG TAC GTG GCC CTC GAT GTG CTC TGC GTG TTG CTG GCT         401
Thr Arg Leu Pro Tyr Val Ala Leu Asp Val Leu Cys Val Leu Leu Ala
  5                  10                  15                  20

GGA TTG CCT TTT GCA ATT CTT ACT TCA AGG CAT ACC CCC TTC CAA CGA         449
Gly Leu Pro Phe Ala Ile Leu Thr Ser Arg His Thr Pro Phe Gln Arg
                  25                  30                  35

GGA GTA TTC TGT AAT GAT GAG TCC ATC AAG TAC CCT TAC AAA GAA GAC         497
Gly Val Phe Cys Asn Asp Glu Ser Ile Lys Tyr Pro Tyr Lys Glu Asp
             40                  45                  50

ACC ATA CCT TAT GCG TTA TTA GGT GGA ATA ATC ATT CCA TTC AGT ATT         545
Thr Ile Pro Tyr Ala Leu Leu Gly Gly Ile Ile Ile Pro Phe Ser Ile
         55                  60                  65

ATC GTT ATT ATT CTT GGA GAA ACC CTG TCT GTT TAC TGT AAC CTT TTG         593
Ile Val Ile Ile Leu Gly Glu Thr Leu Ser Val Tyr Cys Asn Leu Leu
     70                  75                  80

CAC TCA AAT TCC TTT ATC AGG AAT AAC TAC ATA GCC ACT ATT TAC AAA         641
His Ser Asn Ser Phe Ile Arg Asn Asn Tyr Ile Ala Thr Ile Tyr Lys
 85                  90                  95                  100

GCC ATT GGA ACC TTT TTA TTT GGT GCA GCT GCT AGT CAG TCC CTG ACT         689
Ala Ile Gly Thr Phe Leu Phe Gly Ala Ala Ala Ser Gln Ser Leu Thr
                 105                 110                 115

GAC ATT GCC AAG TAT TCA ATA GGC AGA CTG CGG CCT CAC TTC TTG GAT         737
Asp Ile Ala Lys Tyr Ser Ile Gly Arg Leu Arg Pro His Phe Leu Asp
             120                 125                 130

GTT TGT GAT CCA GAT TGG TCA AAA ATC AAC TGC AGC GAT GGT TAC ATT         785
Val Cys Asp Pro Asp Trp Ser Lys Ile Asn Cys Ser Asp Gly Tyr Ile
         135                 140                 145

GAA TAC TAC ATA TGT CGA GGG AAT GCA GAA AGA GTT AAG GAA GGC AGG         833
Glu Tyr Tyr Ile Cys Arg Gly Asn Ala Glu Arg Val Lys Glu Gly Arg
     150                 155                 160

TTG TCC TTC TAT TCA GGC CAC TCT TCG TTT TCC ATG TAC TGC ATG CTG         881
Leu Ser Phe Tyr Ser Gly His Ser Ser Phe Ser Met Tyr Cys Met Leu
165                 170                 175                 180

TTT GTG GCA CTT TAT CTT CAA GCC AGG ATG AAG GGA GAC TGG GCA AGA         929
Phe Val Ala Leu Tyr Leu Gln Ala Arg Met Lys Gly Asp Trp Ala Arg
                 185                 190                 195

CTC TTA CGC CCC ACA CTG CAA TTT GGT CTT GTT GCC GTA TCC ATT TAT         977
Leu Leu Arg Pro Thr Leu Gln Phe Gly Leu Val Ala Val Ser Ile Tyr
             200                 205                 210

GTG GGC CTT TCT CGA GTT TCT GAT TAT AAA CAC CAC TGG AGC GAT GTG        1025
Val Gly Leu Ser Arg Val Ser Asp Tyr Lys His His Trp Ser Asp Val
         215                 220                 225
```

```
TTG ACT GGA CTC ATT CAG GGA GCT CTG GTT GCA ATA TTA GTT GCT GTA      1073
Leu Thr Gly Leu Ile Gln Gly Ala Leu Val Ala Ile Leu Val Ala Val
    230                 235                 240

TAT GTA TCG GAT TTC TTC AAA GAA AGA ACT TCT TTT AAA GAA AGA AAA      1121
Tyr Val Ser Asp Phe Phe Lys Glu Arg Thr Ser Phe Lys Glu Arg Lys
245                 250                 255                 260

GAG GAG GAC TCT CAT ACA ACT CTG CAT GAA ACA CCA ACA ACT GGG AAT      1169
Glu Glu Asp Ser His Thr Thr Leu His Glu Thr Pro Thr Thr Gly Asn
                265                 270                 275

CAC TAT CCG AGC AAT CAC CAG CCT TGAAAGGCAG CAGGGTGCCC AGGTGAAGCT     1223
His Tyr Pro Ser Asn His Gln Pro
            280

GGCCTGTTTT CTAAAGGAAA ATGATTGCCA CAAGGCAAGA GGATGCATCT TTCTTCCTGG    1283

TGTACAAGCC TTTAAAGACT TCTGCTGCTG ATATGCCTCT TGGATGCACA CTTTGTGTGT    1343

ACATAGTTAC CTTTAACTCA GTGGTTATCT AATAGCTCTA AACTCATTAA AAAAACTCCA    1403

AGCCTTCCAC CAAAACAGTG CCCCACCTGT ATACATTTTT ATTAAAAAAA TGTAATGCTT    1463

ATGTATAAAC ATGTATGTAA TATGCTTTCT ATGAATGATG TTTGATTTAA ATATAATACA    1523

TATTAAAATG TATGGGAGAA CCAAAAAAAA AAAAAAAAAA                          1563
```

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 284 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```
Met Phe Asp Lys Thr Arg Leu Pro Tyr Val Ala Leu Asp Val Leu Cys
 1               5                  10                  15

Val Leu Leu Ala Gly Leu Pro Phe Ala Ile Leu Thr Ser Arg His Thr
            20                  25                  30

Pro Phe Gln Arg Gly Val Phe Cys Asn Asp Glu Ser Ile Lys Tyr Pro
        35                  40                  45

Tyr Lys Glu Asp Thr Ile Pro Tyr Ala Leu Leu Gly Gly Ile Ile Ile
    50                  55                  60

Pro Phe Ser Ile Ile Val Ile Ile Leu Gly Glu Thr Leu Ser Val Tyr
65                  70                  75                  80

Cys Asn Leu Leu His Ser Asn Ser Phe Ile Arg Asn Asn Tyr Ile Ala
                85                  90                  95

Thr Ile Tyr Lys Ala Ile Gly Thr Phe Leu Phe Gly Ala Ala Ala Ser
            100                 105                 110

Gln Ser Leu Thr Asp Ile Ala Lys Tyr Ser Ile Gly Arg Leu Arg Pro
        115                 120                 125

His Phe Leu Asp Val Cys Asp Pro Asp Trp Ser Lys Ile Asn Cys Ser
    130                 135                 140
```

```
Asp Gly Tyr Ile Glu Tyr Tyr Ile Cys Arg Gly Asn Ala Glu Arg Val
145                 150                 155                 160

Lys Glu Gly Arg Leu Ser Phe Tyr Ser Gly His Ser Ser Phe Ser Met
                165                 170                 175

Tyr Cys Met Leu Phe Val Ala Leu Tyr Leu Gln Ala Arg Met Lys Gly
            180                 185                 190

Asp Trp Ala Arg Leu Leu Arg Pro Thr Leu Gln Phe Gly Leu Val Ala
        195                 200                 205

Val Ser Ile Tyr Val Gly Leu Ser Arg Val Ser Asp Tyr Lys His His
    210                 215                 220

Trp Ser Asp Val Leu Thr Gly Leu Ile Gln Gly Ala Leu Val Ala Ile
225                 230                 235                 240

Leu Val Ala Val Tyr Val Ser Asp Phe Phe Lys Glu Arg Thr Ser Phe
                245                 250                 255

Lys Glu Arg Lys Glu Glu Asp Ser His Thr Thr Leu His Glu Thr Pro
            260                 265                 270

Thr Thr Gly Asn His Tyr Pro Ser Asn His Gln Pro
        275                 280
```

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1566 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 342..1196

(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 342..1196

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```
CCTGTGGGAG AGAGCGCCGG GATCCGGACG GGGTAGCAAC CGGGGCAGGC CGTGCCGGCT      60

GAGGAGGTCC TGAGGCTACA GAGCTGCCGC GGCTGGCACA CGAGCGCCTC GGCACTAACC     120

GAGTGTTCGC GGGGGCTGTG AGGGGAGGGC CCCGGGCGCC ATTGCTGGCG GTGGGAGCGC     180

CGCCCGGTCT CAGCCCGCCC TCGGCTGCTC TCCTCCTCCG GCTGGGAGGG GCCGTATCTC     240

GGGGCCGTCG CCAGCCCCGG CCCGGGCTCG ATAATCAAGG GCCTCGGCCG TCGTCCCGCA     300

CCTCATTCCA TCGCCCTTGC CGGGCAGCCC GGGCAGAGAC C ATG TTT GAC AAG          353
                                                Met Phe Asp Lys
                                                  1

ACG CGG CTG CCG TAC GTG GCC CTC GAT GTG CTC TGC GTG TTG CTG GCT         401
Thr Arg Leu Pro Tyr Val Ala Leu Asp Val Leu Cys Val Leu Leu Ala
  5                  10                  15                  20
```

```
TCC ATG CCT ATG GCT GTT CTA AAA TTG GGC CAA ATA TAT CCA TTT CAG        449
Ser Met Pro Met Ala Val Leu Lys Leu Gly Gln Ile Tyr Pro Phe Gln
                 25                  30                  35

AGA GGC TTT TTC TGT AAA GAC AAC AGC ATC AAC TAT CCG TAC CAT GAC        497
Arg Gly Phe Phe Cys Lys Asp Asn Ser Ile Asn Tyr Pro Tyr His Asp
             40                  45                  50

AGT ACC GCC GCA TCC ACT GTC CTC ATC CTA GTG GGG GTT GGC TTG CCC        545
Ser Thr Ala Ala Ser Thr Val Leu Ile Leu Val Gly Val Gly Leu Pro
         55                  60                  65

GTT TCC TCT ATT ATT CTT GGA GAA ACC CTG TCT GTT TAC TGT AAC CTT        593
Val Ser Ser Ile Ile Leu Gly Glu Thr Leu Ser Val Tyr Cys Asn Leu
     70                  75                  80

TTG CAC TCA AAT TCC TTT ATC AGT AAT AAC TAC ATA GCC ACT ATT TAC        641
Leu His Ser Asn Ser Phe Ile Ser Asn Asn Tyr Ile Ala Thr Ile Tyr
 85                  90                  95                 100

AAA GCC ATT GGA ACC TTT TTA TTT GGT GCA GCT GCT AGT CAG TCC CTG        689
Lys Ala Ile Gly Thr Phe Leu Phe Gly Ala Ala Ala Ser Gln Ser Leu
                105                 110                 115

ACT GAC ATT GCC AAG TAT TCA ATA GGC AGA CTG CGG CCT CAC TTC TTG        737
Thr Asp Ile Ala Lys Tyr Ser Ile Gly Arg Leu Arg Pro His Phe Leu
            120                 125                 130

GAT GTT TGT GAT CCA GAT TGG TCA AAA ATC AAC TGC AGC GAT GGT TAC        785
Asp Val Cys Asp Pro Asp Trp Ser Lys Ile Asn Cys Ser Asp Gly Tyr
        135                 140                 145

ATT GAA TAC TAC ATA TGT CGA GGG AAT GCA GAA AGA GTT AAG GAA GGC        833
Ile Glu Tyr Tyr Ile Cys Arg Gly Asn Ala Glu Arg Val Lys Glu Gly
    150                 155                 160

AGG TTG TCC TTC TAT TCA GGC CAC TCT TCG TTT TCC ATG TAC TGC ATG        881
Arg Leu Ser Phe Tyr Ser Gly His Ser Ser Phe Ser Met Tyr Cys Met
165                 170                 175                 180

CTG TTT GTG GCA CTT TAT CTT CAA GCC AGG ATG AAG GGA GAC TGG GCA        929
Leu Phe Val Ala Leu Tyr Leu Gln Ala Arg Met Lys Gly Asp Trp Ala
                185                 190                 195

AGA CTC TTA CGC CCC ACA CTG CAA TTT GGT CTT GTT GCC GTA TCC ATT        977
Arg Leu Leu Arg Pro Thr Leu Gln Phe Gly Leu Val Ala Val Ser Ile
            200                 205                 210

TAT GTG GGC CTT TCT CGA GTT TCT GAT TAT AAA CAC CAC TGG AGC GAT       1025
Tyr Val Gly Leu Ser Arg Val Ser Asp Tyr Lys His His Trp Ser Asp
        215                 220                 225

GTG TTG ACT GGA CTC ATT CAG GGA GCT CTG GTT GCA ATA TTA GTT GCT       1073
Val Leu Thr Gly Leu Ile Gln Gly Ala Leu Val Ala Ile Leu Val Ala
    230                 235                 240

GTA TAT GTA TCG GAT TTC TTC AAA GAA AGA ACT TCT TTT AAA GAA AGA       1121
Val Tyr Val Ser Asp Phe Phe Lys Glu Arg Thr Ser Phe Lys Glu Arg
245                 250                 255                 260

AAA GAG GAG GAC TCT CAT ACA ACT CTG CAT GAA ACA CCA ACA ACT GGG       1169
Lys Glu Glu Asp Ser His Thr Thr Leu His Glu Thr Pro Thr Thr Gly
                265                 270                 275

AAT CAC TAT CCG AGC AAT CAC CAG CCT TGAAAGGCAG CAGGGTGCCC             1216
Asn His Tyr Pro Ser Asn His Gln Pro
            280                 285
```

AGGTGAAGCT GGCCTGTTTT CTAAAGGAAA ATGATTGCCA CAAGGCAAGA GGATGCATCT 1276

TTCTTCCTGG TGTACAAGCC TTTAAAGACT TCTGCTGCTG ATATGCCTCT TGGATGCACA 1336

CTTTGTGTGT ACATAGTTAC CTTTAACTCA GTGGTTATCT AATAGCTCTA AACTCATTAA 1396

AAAAACTCCA AGCCTTCCAC CAAAACAGTG CCCCACCTGT ATACATTTTT ATTAAAAAAA 1456

TGTAATGCTT ATGTATAAAC ATGTATGTAA TATGCTTTCT ATGAATGATG TTTGATTTAA 1516

ATATAATACA TATTAAAATG TATGGGAGAA CCAAAAAAAA AAAAAAAAAA 1566

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 285 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Phe Asp Lys Thr Arg Leu Pro Tyr Val Ala Leu Asp Val Leu Cys
1 5 10 15

Val Leu Leu Ala Ser Met Pro Met Ala Val Leu Lys Leu Gly Gln Ile
20 25 30

Tyr Pro Phe Gln Arg Gly Phe Phe Cys Lys Asp Asn Ser Ile Asn Tyr
35 40 45

Pro Tyr His Asp Ser Thr Ala Ala Ser Thr Val Leu Ile Leu Val Gly
50 55 60

Val Gly Leu Pro Val Ser Ser Ile Ile Leu Gly Glu Thr Leu Ser Val
65 70 75 80

Tyr Cys Asn Leu Leu His Ser Asn Ser Phe Ile Ser Asn Asn Tyr Ile
85 90 95

Ala Thr Ile Tyr Lys Ala Ile Gly Thr Phe Leu Phe Gly Ala Ala Ala
100 105 110

Ser Gln Ser Leu Thr Asp Ile Ala Lys Tyr Ser Ile Gly Arg Leu Arg
115 120 125

Pro His Phe Leu Asp Val Cys Asp Pro Asp Trp Ser Lys Ile Asn Cys
130 135 140

Ser Asp Gly Tyr Ile Glu Tyr Tyr Ile Cys Arg Gly Asn Ala Glu Arg
145 150 155 160

Val Lys Glu Gly Arg Leu Ser Phe Tyr Ser Gly His Ser Ser Phe Ser
165 170 175

Met Tyr Cys Met Leu Phe Val Ala Leu Tyr Leu Gln Ala Arg Met Lys
180 185 190

Gly Asp Trp Ala Arg Leu Leu Arg Pro Thr Leu Gln Phe Gly Leu Val
195 200 205

Ala Val Ser Ile Tyr Val Gly Leu Ser Arg Val Ser Asp Tyr Lys His
210 215 220

```
His Trp Ser Asp Val Leu Thr Gly Leu Ile Gln Gly Ala Leu Val Ala
225                 230                 235                 240

Ile Leu Val Ala Val Tyr Val Ser Asp Phe Phe Lys Glu Arg Thr Ser
                245                 250                 255

Phe Lys Glu Arg Lys Glu Glu Asp Ser His Thr Thr Leu His Glu Thr
            260                 265                 270

Pro Thr Thr Gly Asn His Tyr Pro Ser Asn His Gln Pro
        275                 280                 285
```

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1362 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 294..1226

(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 294..1226

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

```
GGCGCAGCTC TGCAAAAGTT TCTGCTCGGG ATCTGGCTCT CTTCCCCTTG GACTTTAGAA      60

CGATTTAGGG TTGACAGAGG AAAGCAGAGG CGCGCAGGAG GAGCAGAAAA CACCACCTTC     120

TGCAGTTGGA GGCAGGCAGC CCCGGCTGCA CTCTAGCCGC CGCGCCCGGA GCCGGGGCCG     180

ACCCGCCACT ATCCGCAGCA GCCTCGGCCA GGAGGCGACC CGGGCGCCTG GGTGTGTGGC     240

TGCTGTTGCG GGACGTCTTC GCGGGGCGGG AGGCTCGCGC CGCAGCCAGC GCC ATG        296
                                                          Met
                                                           1

CAA AAC TAC AAG TAC GAC AAA GCG ATC GTC CCG GAG AGC AAG AAC GGC        344
Gln Asn Tyr Lys Tyr Asp Lys Ala Ile Val Pro Glu Ser Lys Asn Gly
          5                  10                  15

GGC AGC CCG GCG CTC AAC AAC AAC CCG AGG AGG AGC GGC AGC AAG CGG        392
Gly Ser Pro Ala Leu Asn Asn Asn Pro Arg Arg Ser Gly Ser Lys Arg
     20                  25                  30

GTG CTG CTC ATC TGC CTC GAC CTC TTC TGC CTC TTC ATG GCG GGC CTC        440
Val Leu Leu Ile Cys Leu Asp Leu Phe Cys Leu Phe Met Ala Gly Leu
 35                  40                  45

CCC TTC CTC ATC ATC GAG ACA AGC ACC ATC AAG CCT TAC CAC CGA GGG        488
Pro Phe Leu Ile Ile Glu Thr Ser Thr Ile Lys Pro Tyr His Arg Gly
 50                  55                  60                  65

TTT TAC TGC AAT GAT GAG AGC ATC AAG TAC CCA CTG AAA ACT GGT GAG        536
Phe Tyr Cys Asn Asp Glu Ser Ile Lys Tyr Pro Leu Lys Thr Gly Glu
                70                  75                  80
```

```
ACA ATA AAT GAC GCT GTG CTC TGT GCC GTG GGG ATC GTC ATT GCC ATC          584
Thr Ile Asn Asp Ala Val Leu Cys Ala Val Gly Ile Val Ile Ala Ile
            85                  90                  95

CTC GCG ATC ATC ACG GGG GAA TTC TAC CGG ATC TAT TAC CTG AAG AAG          632
Leu Ala Ile Ile Thr Gly Glu Phe Tyr Arg Ile Tyr Tyr Leu Lys Lys
        100                 105                 110

TCG CGG TCG ACG ATT CAG AAC CCC TAC GTG GCA GCA CTC TAT AAG CAA          680
Ser Arg Ser Thr Ile Gln Asn Pro Tyr Val Ala Ala Leu Tyr Lys Gln
    115                 120                 125

GTG GGC TGC TTC CTC TTT GGC TGT GCC ATC AGC CAG TCT TTC ACA GAC          728
Val Gly Cys Phe Leu Phe Gly Cys Ala Ile Ser Gln Ser Phe Thr Asp
130                 135                 140                 145

ATT GCC AAA GTG TCC ATA GGG CGC CTG CGT CCT CAC TTC TTG AGT GTC          776
Ile Ala Lys Val Ser Ile Gly Arg Leu Arg Pro His Phe Leu Ser Val
                150                 155                 160

TGC AAC CCT GAT TTC AGC CAG ATC AAC TGC TCT GAA GGC TAC ATT CAG          824
Cys Asn Pro Asp Phe Ser Gln Ile Asn Cys Ser Glu Gly Tyr Ile Gln
            165                 170                 175

AAC TAC AGA TGC AGA GGT GAT GAC AGC AAA GTC CAG GAA GCC AGG AAG          872
Asn Tyr Arg Cys Arg Gly Asp Asp Ser Lys Val Gln Glu Ala Arg Lys
        180                 185                 190

TCC TTC TTC TCT GGC CAT GCC TCC TTC TCC ATG TAC ACT ATG CTG TAT          920
Ser Phe Phe Ser Gly His Ala Ser Phe Ser Met Tyr Thr Met Leu Tyr
    195                 200                 205

TTG GTG CTA TAC CTG CAG GCC CGC TTC ACT TGG CGA GGA GCC CGC CTG          968
Leu Val Leu Tyr Leu Gln Ala Arg Phe Thr Trp Arg Gly Ala Arg Leu
210                 215                 220                 225

CTC CGG CCC CTC CTG CAG TTC ACC TTG ATC ATG ATG GCC TTC TAC ACG         1016
Leu Arg Pro Leu Leu Gln Phe Thr Leu Ile Met Met Ala Phe Tyr Thr
                230                 235                 240

GGA CTG TCT CGC GTA TCA GAC CAC AAG CAC CAT CCC AGT GAT GTT CTG         1064
Gly Leu Ser Arg Val Ser Asp His Lys His His Pro Ser Asp Val Leu
            245                 250                 255

GCA GGA TTT GCT CAA GGA GCC CTG GTG GCC TGC TGC ATA GTT TTC TTC         1112
Ala Gly Phe Ala Gln Gly Ala Leu Val Ala Cys Cys Ile Val Phe Phe
        260                 265                 270

GTG TCT GAC CTC TTC AAG ACT AAG ACG ACG CTC TCC CTG CCT GCC CCT         1160
Val Ser Asp Leu Phe Lys Thr Lys Thr Thr Leu Ser Leu Pro Ala Pro
    275                 280                 285

GCT ATC CGG AAG GAA ATC CTT TCA CCT GTG GAC ATT ATT GAC AGG AAC         1208
Ala Ile Arg Lys Glu Ile Leu Ser Pro Val Asp Ile Ile Asp Arg Asn
290                 295                 300                 305

AAT CAC CAC AAC ATG ATG TAGGTGCCAC CCACCTCCTG AGCTGTTTTT                1256
Asn His His Asn Met Met
                310

GTAAAATGAC TGCTGACAGC AAGTTCTTGC TGCTCTCCAA TCTCATCAGA CAGTAGAATG       1316

TAGGGAAAAA CTTTTGCCCG ACTGATTTTT AAAAAAAAAA AAAAAA                      1362
```

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 311 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

```
Met Gln Asn Tyr Lys Tyr Asp Lys Ala Ile Val Pro Glu Ser Lys Asn
 1               5                  10                  15

Gly Gly Ser Pro Ala Leu Asn Asn Asn Pro Arg Arg Ser Gly Ser Lys
            20                  25                  30

Arg Val Leu Leu Ile Cys Leu Asp Leu Phe Cys Leu Phe Met Ala Gly
        35                  40                  45

Leu Pro Phe Leu Ile Ile Glu Thr Ser Thr Ile Lys Pro Tyr His Arg
    50                  55                  60

Gly Phe Tyr Cys Asn Asp Glu Ser Ile Lys Tyr Pro Leu Lys Thr Gly
65                  70                  75                  80

Glu Thr Ile Asn Asp Ala Val Leu Cys Ala Val Gly Ile Val Ile Ala
                85                  90                  95

Ile Leu Ala Ile Ile Thr Gly Glu Phe Tyr Arg Ile Tyr Tyr Leu Lys
            100                 105                 110

Lys Ser Arg Ser Thr Ile Gln Asn Pro Tyr Val Ala Ala Leu Tyr Lys
        115                 120                 125

Gln Val Gly Cys Phe Leu Phe Gly Cys Ala Ile Ser Gln Ser Phe Thr
    130                 135                 140

Asp Ile Ala Lys Val Ser Ile Gly Arg Leu Arg Pro His Phe Leu Ser
145                 150                 155                 160

Val Cys Asn Pro Asp Phe Ser Gln Ile Asn Cys Ser Glu Gly Tyr Ile
                165                 170                 175

Gln Asn Tyr Arg Cys Arg Gly Asp Asp Ser Lys Val Gln Glu Ala Arg
            180                 185                 190

Lys Ser Phe Phe Ser Gly His Ala Ser Phe Ser Met Tyr Thr Met Leu
        195                 200                 205

Tyr Leu Val Leu Tyr Leu Gln Ala Arg Phe Thr Trp Arg Gly Ala Arg
    210                 215                 220

Leu Leu Arg Pro Leu Leu Gln Phe Thr Leu Ile Met Met Ala Phe Tyr
225                 230                 235                 240

Thr Gly Leu Ser Arg Val Ser Asp His Lys His His Pro Ser Asp Val
                245                 250                 255

Leu Ala Gly Phe Ala Gln Gly Ala Leu Val Ala Cys Cys Ile Val Phe
            260                 265                 270

Phe Val Ser Asp Leu Phe Lys Thr Lys Thr Thr Leu Ser Leu Pro Ala
        275                 280                 285

Pro Ala Ile Arg Lys Glu Ile Leu Ser Pro Val Asp Ile Ile Asp Arg
    290                 295                 300
```

Asn Asn His His Asn Met Met
305 310

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1232 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 4..833

(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 4..833

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

```
ACC ATG CAG CGG AGG TGG GTC TTC GTG CTG CTC GAC GTG CTG TGC TTA      48
    Met Gln Arg Arg Trp Val Phe Val Leu Leu Asp Val Leu Cys Leu
      1               5                  10                  15

CTG GTC GCC TCC CTG CCC TTC GCT ATC CTG ACG CTG GTG AAC GCC CCG      96
Leu Val Ala Ser Leu Pro Phe Ala Ile Leu Thr Leu Val Asn Ala Pro
                20                  25                  30

TAC AAG CGA GGA TTT TAC TGC GGG GAT GAC TCC ATC CGG TAC CCC TAC     144
Tyr Lys Arg Gly Phe Tyr Cys Gly Asp Asp Ser Ile Arg Tyr Pro Tyr
            35                  40                  45

CGT CCA GAT ACC ATC ACC CAC GGG CTC ATG GCT GGG GTC ACC ATC ACG     192
Arg Pro Asp Thr Ile Thr His Gly Leu Met Ala Gly Val Thr Ile Thr
        50                  55                  60

GCC ACC GTC ATC CTT GTC TCG GCC GGG GAA GCC TAC CTG GTG TAC ACA     240
Ala Thr Val Ile Leu Val Ser Ala Gly Glu Ala Tyr Leu Val Tyr Thr
    65                  70                  75

GAC CGG CTC TAT TCT CGC TCG GAC TTC AAC AAC TAC GTG GCT GCT GTA     288
Asp Arg Leu Tyr Ser Arg Ser Asp Phe Asn Asn Tyr Val Ala Ala Val
80                  85                  90                  95

TAC AAG GTG CTG GGG ACC TTC CTG TTT GGG GCT GCC GTG AGC CAG TCT     336
Tyr Lys Val Leu Gly Thr Phe Leu Phe Gly Ala Ala Val Ser Gln Ser
                100                 105                 110

CTG ACA GAC CTG GCC AAG TAC ATG ATT GGG CGT CTG AAG CCC AAC TTC     384
Leu Thr Asp Leu Ala Lys Tyr Met Ile Gly Arg Leu Lys Pro Asn Phe
            115                 120                 125

CTA GCC GTC TGC GAC CCC GAC TGG AGC CGG GTC AAC TGC TCG GTC TAT     432
Leu Ala Val Cys Asp Pro Asp Trp Ser Arg Val Asn Cys Ser Val Tyr
        130                 135                 140

GTG CAG CTG GAG AAG GTG TGC AGG GGA AAC CCT GCT GAT GTC ACC GAG     480
Val Gln Leu Glu Lys Val Cys Arg Gly Asn Pro Ala Asp Val Thr Glu
    145                 150                 155

GCC AGG TTG TCT TTC TAC TCG GGA CAC TCT TCC TTT GGG ATG TAC TGC     528
Ala Arg Leu Ser Phe Tyr Ser Gly His Ser Ser Phe Gly Met Tyr Cys
160                 165                 170                 175
```

```
ATG GTG TTC TTG GCG CTG TAT GTG CAG GCA CGA CTC TGT TGG AAG TGG          576
Met Val Phe Leu Ala Leu Tyr Val Gln Ala Arg Leu Cys Trp Lys Trp
                180                 185                 190

GCA CGG CTG CTG CGA CCC ACA GTC CAG TTC TTC CTG GTG GCC TTT GCC          624
Ala Arg Leu Leu Arg Pro Thr Val Gln Phe Phe Leu Val Ala Phe Ala
            195                 200                 205

CTC TAC GTG GGC TAC ACC CGC GTG TCT GAT TAC AAA CAC CAC TGG AGC          672
Leu Tyr Val Gly Tyr Thr Arg Val Ser Asp Tyr Lys His His Trp Ser
        210                 215                 220

GAT GTC CTT GTT GGC CTC CTG CAG GGG GCA CTG GTG GCT GCC CTC ACT          720
Asp Val Leu Val Gly Leu Leu Gln Gly Ala Leu Val Ala Ala Leu Thr
    225                 230                 235

GTC TGC TAC ATC TCA GAC TTC TTC AAA GCC CGA CCC CCA CAG CAC TGT          768
Val Cys Tyr Ile Ser Asp Phe Phe Lys Ala Arg Pro Pro Gln His Cys
240                 245                 250                 255

CTG AAG GAG GAG GAG CTG GAA CGG AAG CCC AGC CTG TCA CTG ACG TTG          816
Leu Lys Glu Glu Glu Leu Glu Arg Lys Pro Ser Leu Ser Leu Thr Leu
                260                 265                 270

ACC CTG GGG CGA GGC TG ACCACAACCA CTTATGGGAT ACCCGCACTC                  863
Thr Leu Gly Arg Gly
            275

TTCTTCCTGA GGCCGGACCC CGCCCAGGCA GGGAGCTGCT GTGAGTCCAG CTGATGCCCA        923

CCCAGGTGGT CCCTCCAGCC TGGTTAGGCA CTGAGGGTTC TGGACGGGCT CCAGGAACCC        983

TGGGCTGATG GGAGCAGTGA GCGGTTCCGC TGCCCCCTGC CCTGCACTGG ACCAGGAGTC       1043

TGGAGATGCC TGGGTAGCCC TCAGCATTTG GAGGGGAACC TGTTCCCGTC GGTCCCCAAA       1103

TATCCCCTTC TTTTTATGGG GTTAAGGAAG GGACCGAGAG ATCAGATAGT TGCTGTTTTG       1163

TAAAATGTAA TGTATATGTG GTTTTTAGTA AAATAGGGCA CCTGTTTCAC AAAAAAAAAA       1223

AAAAAAAAA                                                               1232
```

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 276 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

```
Met Gln Arg Arg Trp Val Phe Val Leu Leu Asp Val Leu Cys Leu Leu
 1               5                  10                  15

Val Ala Ser Leu Pro Phe Ala Ile Leu Thr Leu Val Asn Ala Pro Tyr
            20                  25                  30

Lys Arg Gly Phe Tyr Cys Gly Asp Asp Ser Ile Arg Tyr Pro Tyr Arg
        35                  40                  45

Pro Asp Thr Ile Thr His Gly Leu Met Ala Gly Val Thr Ile Thr Ala
    50                  55                  60
```

Thr Val Ile Leu Val Ser Ala Gly Glu Ala Tyr Leu Val Tyr Thr Asp
65 70 75 80

Arg Leu Tyr Ser Arg Ser Asp Phe Asn Asn Tyr Val Ala Ala Val Tyr
85 90 95

Lys Val Leu Gly Thr Phe Leu Phe Gly Ala Ala Val Ser Gln Ser Leu
100 105 110

Thr Asp Leu Ala Lys Tyr Met Ile Gly Arg Leu Lys Pro Asn Phe Leu
115 120 125

Ala Val Cys Asp Pro Asp Trp Ser Arg Val Asn Cys Ser Val Tyr Val
130 135 140

Gln Leu Glu Lys Val Cys Arg Gly Asn Pro Ala Asp Val Thr Glu Ala
145 150 155 160

Arg Leu Ser Phe Tyr Ser Gly His Ser Ser Phe Gly Met Tyr Cys Met
165 170 175

Val Phe Leu Ala Leu Tyr Val Gln Ala Arg Leu Cys Trp Lys Trp Ala
180 185 190

Arg Leu Leu Arg Pro Thr Val Gln Phe Phe Leu Val Ala Phe Ala Leu
195 200 205

Tyr Val Gly Tyr Thr Arg Val Ser Asp Tyr Lys His His Trp Ser Asp
210 215 220

Val Leu Val Gly Leu Leu Gln Gly Ala Leu Val Ala Ala Leu Thr Val
225 230 235 240

Cys Tyr Ile Ser Asp Phe Phe Lys Ala Arg Pro Pro Gln His Cys Leu
245 250 255

Lys Glu Glu Glu Leu Glu Arg Lys Pro Ser Leu Ser Leu Thr Leu Thr
260 265 270

Leu Gly Arg Gly
275

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 283 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Met Phe Asp Lys Thr Arg Leu Pro Tyr Val Ala Leu Asp Val Ile Cys
1 5 10 15

Val Leu Leu Ala Gly Leu Pro Phe Ala Ile Leu Thr Ser Arg His Thr
20 25 30

Pro Phe Gln Arg Gly Ile Phe Cys Asn Asp Asp Ser Ile Lys Tyr Pro
35 40 45

Tyr Lys Glu Asp Thr Ile Pro Tyr Ala Leu Leu Gly Gly Ile Val Ile
50 55 60

Pro Phe Cys Ile Ile Val Met Ser Ile Gly Glu Ser Leu Ser Val Tyr
65 70 75 80

Phe Asn Val Leu His Ser Asn Ser Phe Val Gly Asn Pro Tyr Ile Ala
85 90 95

Thr Ile Tyr Lys Ala Val Gly Ala Phe Leu Phe Gly Val Ser Ala Ser
100 105 110

Gln Ser Leu Thr Asp Ile Ala Lys Tyr Thr Ile Gly Ser Leu Arg Pro
115 120 125

His Phe Leu Ala Ile Cys Asn Pro Asp Trp Ser Lys Ile Asn Cys Ser
130 135 140

Asp Gly Tyr Ile Glu Asp Tyr Ile Cys Gln Gly Asn Glu Glu Lys Val
145 150 155 160

Lys Glu Gly Arg Leu Ser Phe Tyr Ser Gly His Ser Ser Phe Ser Met
165 170 175

Tyr Cys Met Leu Phe Val Ala Leu Tyr Leu Gln Ala Arg Met Lys Gly
180 185 190

Asp Trp Ala Arg Leu Leu Arg Pro Met Leu Gln Phe Gly Leu Ile Ala
195 200 205

Phe Ser Ile Tyr Val Gly Leu Ser Arg Val Ser Asp Tyr Lys His His
210 215 220

Trp Ser Asp Val Thr Val Gly Leu Ile Gln Gly Ala Ala Met Ala Ile
225 230 235 240

Leu Val Ala Leu Tyr Val Ser Asp Phe Phe Lys Asp Thr His Ser Tyr
245 250 255

Lys Glu Arg Lys Glu Glu Asp Pro His Thr Thr Leu His Glu Thr Ala
260 265 270

Ser Ser Arg Asn Tyr Ser Thr Asn His Glu Pro
275 280

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 284 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Met Phe Asp Lys Thr Arg Leu Pro Tyr Val Ala Leu Asp Val Leu Cys
1 5 10 15

Val Leu Leu Ala Gly Leu Pro Phe Ala Ile Leu Thr Ser Arg His Thr
20 25 30

Pro Phe Gln Arg Gly Val Phe Cys Asn Asp Glu Ser Ile Lys Tyr Pro
35 40 45

Tyr Lys Glu Asp Thr Ile Pro Tyr Ala Leu Leu Gly Gly Ile Ile Ile
50 55 60

Pro Phe Ser Ile Ile Val Ile Ile Leu Gly Glu Thr Leu Ser Val Tyr
65 70 75 80

Cys Asn Leu Leu His Ser Asn Ser Phe Ile Arg Asn Asn Tyr Ile Ala
85 90 95

Thr Ile Tyr Lys Ala Ile Gly Thr Phe Leu Phe Gly Ala Ala Ala Ser
100 105 110

Gln Ser Leu Thr Asp Ile Ala Lys Tyr Ser Ile Gly Arg Leu Arg Pro
115 120 125

His Phe Leu Asp Val Cys Asp Pro Asp Trp Ser Lys Ile Asn Cys Ser
130 135 140

Asp Gly Tyr Ile Glu Tyr Tyr Ile Cys Arg Gly Asn Ala Glu Arg Val
145 150 155 160

Lys Glu Gly Arg Leu Ser Phe Tyr Ser Gly His Ser Ser Phe Ser Met
165 170 175

Tyr Cys Met Leu Phe Val Ala Leu Tyr Leu Gln Ala Arg Met Lys Gly
180 185 190

Asp Trp Ala Arg Leu Leu Arg Pro Thr Leu Gln Phe Gly Leu Val Ala
195 200 205

Val Ser Ile Tyr Val Gly Leu Ser Arg Val Ser Asp Tyr Lys His His
210 215 220

Trp Ser Asp Val Leu Thr Gly Leu Ile Gln Gly Ala Leu Val Ala Ile
225 230 235 240

Leu Val Ala Val Tyr Val Ser Asp Phe Phe Lys Glu Arg Thr Ser Phe
245 250 255

Lys Glu Arg Lys Glu Glu Asp Ser His Thr Thr Leu His Glu Thr Pro
260 265 270

Thr Thr Gly Asn His Tyr Pro Ser Asn His Gln Pro
275 280

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 285 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Met Phe Asp Lys Thr Arg Leu Pro Tyr Val Ala Leu Asp Val Leu Cys
1 5 10 15

Val Leu Leu Ala Ser Met Pro Met Ala Val Leu Lys Leu Gly Gln Ile
20 25 30

Tyr Pro Phe Gln Arg Gly Phe Phe Cys Lys Asp Asn Ser Ile Asn Tyr
35 40 45

Pro Tyr His Asp Ser Thr Ala Ala Ser Thr Val Leu Ile Leu Val Gly
50 55 60

Val Gly Leu Pro Val Ser Ser Ile Ile Leu Gly Glu Thr Leu Ser Val
65 70 75 80

Tyr Cys Asn Leu Leu His Ser Asn Ser Phe Ile Arg Asn Asn Tyr Ile
85 90 95

Ala Thr Ile Tyr Lys Ala Ile Gly Thr Phe Leu Phe Gly Ala Ala Ala
100 105 110

Ser Gln Ser Leu Thr Asp Ile Ala Lys Tyr Ser Ile Gly Arg Leu Arg
115 120 125

Pro His Phe Leu Asp Val Cys Asp Pro Asp Trp Ser Lys Ile Asn Cys
130 135 140

Ser Asp Gly Tyr Ile Glu Tyr Tyr Ile Cys Arg Gly Asn Ala Glu Arg
145 150 155 160

Val Lys Glu Gly Arg Leu Ser Phe Tyr Ser Gly His Ser Ser Phe Ser
165 170 175

Met Tyr Cys Met Leu Phe Val Ala Leu Tyr Leu Gln Ala Arg Met Lys
180 185 190

Gly Asp Trp Ala Arg Leu Leu Arg Pro Thr Leu Gln Phe Gly Leu Val
195 200 205

Ala Val Ser Ile Tyr Val Gly Leu Ser Arg Val Ser Asp Tyr Lys His
210 215 220

His Trp Ser Asp Val Leu Thr Gly Leu Ile Gln Gly Ala Leu Val Ala
225 230 235 240

Ile Leu Val Ala Val Tyr Val Ser Asp Phe Phe Lys Glu Arg Thr Ser
245 250 255

Phe Lys Glu Arg Lys Glu Glu Asp Ser His Thr Thr Leu His Glu Thr
260 265 270

Pro Thr Thr Gly Asn His Tyr Pro Ser Asn His Gln Pro
275 280 285

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 311 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Met Gln Asn Tyr Lys Tyr Asp Lys Ala Ile Val Pro Glu Ser Lys Asn
1 5 10 15

Gly Gly Ser Pro Ala Leu Asn Asn Asn Pro Arg Arg Ser Gly Ser Lys
20 25 30

Arg Val Leu Leu Ile Cys Leu Asp Leu Phe Cys Leu Phe Met Ala Gly
35 40 45

Leu Pro Phe Leu Ile Ile Glu Thr Ser Thr Ile Lys Pro Tyr His Arg
50 55 60

Gly Phe Tyr Cys Asn Asp Glu Ser Ile Lys Tyr Pro Leu Lys Thr Gly
65 70 75 80

Glu Thr Ile Asn Asp Ala Val Leu Cys Ala Val Gly Ile Val Ile Ala
85 90 95

Ile Leu Ala Ile Ile Thr Gly Glu Phe Tyr Arg Ile Tyr Tyr Leu Lys
100 105 110

Lys Ser Arg Ser Thr Ile Gln Asn Pro Tyr Val Ala Ala Leu Tyr Lys
115 120 125

Gln Val Gly Cys Phe Leu Phe Gly Cys Ala Ile Ser Gln Ser Phe Thr
130 135 140

Asp Ile Ala Lys Val Ser Ile Gly Arg Leu Arg Pro His Phe Leu Ser
145 150 155 160

Val Cys Asn Pro Asp Phe Ser Gln Ile Asn Cys Ser Glu Gly Tyr Ile
165 170 175

Gln Asn Tyr Arg Cys Arg Gly Asp Asp Ser Lys Val Gln Glu Ala Arg
180 185 190

Lys Ser Phe Phe Ser Gly His Ala Ser Phe Ser Met Tyr Thr Met Leu
195 200 205

Tyr Leu Val Leu Tyr Leu Gln Ala Arg Phe Thr Trp Arg Gly Ala Arg
210 215 220

Leu Leu Arg Pro Leu Leu Gln Phe Thr Leu Ile Met Met Ala Phe Tyr
225 230 235 240

Thr Gly Leu Ser Arg Val Ser Asp His Lys His His Pro Ser Asp Val
245 250 255

Leu Ala Gly Phe Ala Gln Gly Ala Leu Val Ala Cys Cys Ile Val Phe
260 265 270

Phe Val Ser Asp Leu Phe Lys Thr Lys Thr Thr Leu Ser Leu Pro Ala
275 280 285

Pro Ala Ile Arg Lys Glu Ile Leu Ser Pro Val Asp Ile Ile Asp Arg
290 295 300

Asn Asn His His Asn Met Met
305 310

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 276 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Met Gln Arg Arg Trp Val Phe Val Leu Leu Asp Val Leu Cys Leu Leu
1 5 10 15

Val Ala Ser Leu Pro Phe Ala Ile Leu Thr Leu Val Asn Ala Pro Tyr
20 25 30

Lys Arg Gly Phe Tyr Cys Gly Asp Asp Ser Ile Arg Tyr Pro Tyr Arg
35 40 45

Pro Asp Thr Ile Thr His Gly Leu Met Ala Gly Val Thr Ile Thr Ala
50 55 60

Thr Val Ile Leu Val Ser Ala Gly Glu Ala Tyr Leu Val Tyr Thr Asp
65 70 75 80

Arg Leu Tyr Ser Arg Ser Asp Phe Asn Asn Tyr Val Ala Ala Val Tyr
85 90 95

Lys Val Leu Gly Thr Phe Leu Phe Gly Ala Ala Val Ser Gln Ser Leu
100 105 110

Thr Asp Leu Ala Lys Tyr Met Ile Gly Arg Leu Lys Pro Asn Phe Leu
115 120 125

Ala Val Cys Asp Pro Asp Trp Ser Arg Val Asn Cys Ser Val Tyr Val
130 135 140

Gln Leu Glu Lys Val Cys Arg Gly Asn Pro Ala Asp Val Thr Glu Ala
145 150 155 160

Arg Leu Ser Phe Tyr Ser Gly His Ser Ser Phe Gly Met Tyr Cys Met
165 170 175

Val Phe Leu Ala Leu Tyr Val Gln Ala Arg Leu Cys Trp Lys Trp Ala
180 185 190

Arg Leu Leu Arg Pro Thr Val Gln Phe Phe Leu Val Ala Phe Ala Leu
195 200 205

Tyr Val Gly Tyr Thr Arg Val Ser Asp Tyr Lys His His Trp Ser Asp
210 215 220

Val Leu Val Gly Leu Leu Gln Gly Ala Leu Val Ala Ala Leu Thr Val
225 230 235 240

Cys Tyr Ile Ser Asp Phe Phe Lys Ala Arg Pro Pro Gln His Cys Leu
245 250 255

Lys Glu Glu Glu Leu Glu Arg Lys Pro Ser Leu Ser Leu Thr Leu Thr
260 265 270

Leu Gly Arg Gly
275

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

GGCTCTAGAT ATTAATAGTA ATCAATTAC 29

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

CCTCACGCAT GCACCATGGT AATAGC 26

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

GGTGCATGCG TGAGGCTCCG GTGC 24

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

GTAGTTTTCA CGGTACCTGA AATGGAAG 28

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 30 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

GGCATGGTAC CATGTTTGAC AAGACGCGGC 30

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

CATATGTAGT ATTCAATGTA ACC 23

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 47 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

TGATGGCTAG CATGCAGAGA AGATGGGTCT TCGTGCTGCT CGACGTG 47

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

AGTGCGGGAT CCCATAAGTG GTTG 24

What Is Claimed Is:

1. An isolated polynucleotide encoding human phosphatidic acid phosphatase wherein said polynucleotide encodes a protein comprising a polypeptide sequence selected from the group consisting of (i) the sequence at amino acid number 1 to amino acid number 284 in Figure 1 (SEQ ID NO:2), (ii) the sequence at amino acid number 1 to amino acid number 285 in Figure 2 (SEQ ID NO:4), and (iii) the sequence at amino acid number 1 to amino acid number 276 in Figure 4 (SEQ ID NO:8).

2. An isolated human phosphatidic acid phosphatase protein, wherein said protein comprises a polypeptide sequence selected from the group consisting of (i) the sequence at amino acid number 1 to amino acid number 284 in Figure 1 (SEQ ID NO:2), (ii) the sequence at amino acid number 1 to amino acid number 285 in Figure 2 (SEQ ID NO:4), and (iii) the sequence at amino acid number 1 to amino acid number 276 in Figure 4 (SEQ ID NO:8).

3. A method of preparing a human phosphatidic acid phosphatase-$\beta$ protein comprising the steps of (i) transforming a host cell with an expression vector comprising a polynucleotide encoding human phosphatidic acid phosphatase, (ii) culturing said transformed host cells which express said protein and (iii) isolating said protein.

4. The method of claim 3, wherein said polynucleotide encoding human phosphatidic acid is selected from the group consisting of (i) the sequence at amino acid number 1 to amino acid number 284 in Figure 1 (SEQ ID NO:2), (ii) the sequence at amino acid number 1 to amino acid number 285 in Figure 2 (SEQ ID NO:4), (iii) the sequence at amino acid number 1 to amino acid number 311 in Figure 3 (SEQ ID NO:6), and (iv) the sequence at

amino acid number 1 to amino acid number 276 in Figure 4 (SEQ ID NO:8).

5. A method of dephosphorylating a substrate comprising recombinantly producing a human phosphatidic acid phosphatase protein and contacting said substrate with an effective amount of said recombinantly produced human phosphatidic acid phosphatase protein such that said protein catalyzes the dephosphorylation of said substrate.

6. The method of claim 5, wherein said protein comprises the polypeptide sequence at amino acid number 1 to amino acid number 284 in Figure 1 (SEQ ID NO:2).

7. The method of claim 5, wherein said protein comprises the polypeptide sequence at amino acid number 1 to amino acid number 285 in Figure 2 (SEQ ID NO:4).

8. The method of claim 5, wherein said protein comprises the polypeptide sequence at amino acid number 1 to amino acid number 311 in Figure 3 (SEQ ID NO:6).

9. The method of claim 5, wherein said protein comprises the polypeptide sequence at amino acid number 1 to amino acid number 276 in Figure 4 (SEQ ID NO:8).

10. The method of claim 5, wherein said substrate is selected from the group consisting of phosphatidic acid, lysophosphatidic acid, ceramide 1-phosphate, and sphingosine 1-phosphate.

11. The method of claim 5, wherein said contacting is effected *in vitro*, and further comprises the step of isolating said dephosphoryled substrate.

12. The method of claim 5, wherein said contacting step occurs *in vivo* and is effected by the administration of said human phosphatidic acid phosphatase to a mammal in need thereof.

13. A method of dephosphorylating a substrate comprising contacting said substrate with an effective amount of isolated human phosphatidic acid phosphatase protein such that said protein catalyzes the dephosphorylation of said substrate, wherein said substrate is selected from the group consisting of lysophosphatidic acid, ceramide 1-phosphate, and sphingosine 1-phosphate.

## Fig. 1A

```
CCTGTGGGAGAGAGCGCCGGGATCCGGACGGGGTAGCAACCGGGGCAGGCCGTGCCGGCTGA    62
GGAGGTCCTGAGGCTACAGAGCTGCCGCGGCTGGCACACGAGCGCCTCGGCACTAACCGA     122
GTGTTCGCGGGGGCTGTGAGGGGAGGGCCCCGGGCGCCATTGCTGGCGGTGGGAGCGCCG     182
CCCGGTCTCAGCCCGCCCTCGGCTGCTCTCCTCCTCCGGCTGGGAGGGGCCGTATCTCGG     242
GGCCGTCGCCAGCCCCGGCCCGGGCTCGATAATCAAGGGCCTCGGCCGTCGTCCCGCACC     302
TCATTCCATCGCCCTTGCCGGGCAGCCCGGGCAGAGACC ATG TTT GAC AAG ACG       356
                                        Met Phe Asp Lys Thr
                                                             5
CGG CTG CCG TAC GTG GCC CTC GAT GTG CTC TGC GTG TTG CTG GCT       401
Arg Leu Pro Tyr Val Ala Leu Asp Val Leu Cys Val Leu Leu Ala
            10                  15                  20
GGA TTG CCT TTT GCA ATT CTT ACT TCA AGG CAT ACC CCC TTC CAA       446
Gly Leu Pro Phe Ala Ile Leu Thr Ser Arg His Thr Pro Phe Gln
        25                  30                  35
CGA GGA GTA TTC TGT AAT GAT GAG TCC ATC AAG TAC CCT TAC AAA       491
Arg Gly Val Phe Cys Asn Asp Glu Ser Ile Lys Tyr Pro Tyr Lys
    40                  45                  50
GAA GAC ACC ATA CCT TAT GCG TTA TTA GGT GGA ATA ATC ATT CCA       536
Glu Asp Thr Ile Pro Tyr Ala Leu Leu Gly Gly Ile Ile Ile Pro
55                  60                  65
TTC AGT ATT ATC GTT ATT ATT CTT GGA GAA ACC CTG TCT GTT TAC       581
Phe Ser Ile Ile Val Ile Ile Leu Gly Glu Thr Leu Ser Val Tyr
            70                  75                  80
TGT AAC CTT TTG CAC TCA AAT TCC TTT ATC AGG AAT AAC TAC ATA       626
Cys Asn Leu Leu His Ser Asn Ser Phe Ile Arg Asn Asn Tyr Ile
        85                  90                  95
GCC ACT ATT TAC AAA GCC ATT GGA ACC TTT TTA TTT GGT GCA GCT       671
Ala Thr Ile Tyr Lys Ala Ile Gly Thr Phe Leu Phe Gly Ala Ala
    100                 105                 110
GCT AGT CAG TCC CTG ACT GAC ATT GCC AAG TAT TCA ATA GGC AGA       716
Ala Ser Gln Ser Leu Thr Asp Ile Ala Lys Tyr Ser Ile Gly Arg
115                 120                 125
CTG CGG CCT CAC TTC TTG GAT GTT TGT GAT CCA GAT TGG TCA AAA       761
Leu Arg Pro His Phe Leu Asp Val Cys Asp Pro Asp Trp Ser Lys
            130                 135                 140
ATC AAC TGC AGC GAT GGT TAC ATT GAA TAC TAC ATA TGT CGA GGG       806
Ile Asn Cys Ser Asp Gly Tyr Ile Glu Tyr Tyr Ile Cys Arg Gly
        145                 150                 155
AAT GCA GAA AGA GTT AAG GAA GGC AGG TTG TCC TTC TAT TCA GGC       851
Asn Ala Glu Arg Val Lys Glu Gly Arg Leu Ser Phe Tyr Ser Gly
    160                 165                 170
CAC TCT TCG TTT TCC ATG TAC TGC ATG CTG TTT GTG GCA CTT TAT       896
His Ser Ser Phe Ser Met Tyr Cys Met Leu Phe Val Ala Leu Tyr
175                 180                 185
CTT CAA GCC AGG ATG AAG GGA GAC TGG GCA AGA CTC TTA CGC CCC       941
Leu Gln Ala Arg Met Lys Gly Asp Trp Ala Arg Leu Leu Arg Pro
            190                 195                 200
ACA CTG CAA TTT GGT CTT GTT GCC GTA TCC ATT TAT GTG GGC CTT       986
Thr Leu Gln Phe Gly Leu Val Ala Val Ser Ile Tyr Val Gly Leu
        205                 210                 215
TCT CGA GTT TCT GAT TAT AAA CAC CAC TGG AGC GAT GTG TTG ACT      1031
Ser Arg Val Ser Asp Tyr Lys His His Trp Ser Asp Val Leu Thr
    220                 225                 230
GGA CTC ATT CAG GGA GCT CTG GTT GCA ATA TTA GTT GCT GTA TAT      1076
Gly Leu Ile Gln Gly Ala Leu Val Ala Ile Leu Val Ala Val Tyr
235                 240                 245
GTA TCG GAT TTC TTC AAA GAA AGA ACT TCT TTT AAA GAA AGA AAA      1121
Val Ser Asp Phe Phe Lys Glu Arg Thr Ser Phe Lys Glu Arg Lys
            250                 255                 260
```

## Fig. 1B

```
GAG GAG GAC TCT CAT ACA ACT CTG CAT GAA ACA CCA ACA ACT GGG     1166
Glu Glu Asp Ser His Thr Thr Leu His Glu Thr Pro Thr Thr Gly
                265                 270                 275
AAT CAC TAT CCG AGC AAT CAC CAG CCT TGA AAG GCAGCAGGGTGCCCAG    1215
Asn His Tyr Pro Ser Asn His Gln Pro ***
                280
GTGAAGCTGGCCTGTTTTCTAAAGGAAAATGATTGCCACAAGGCAAGAGGATGCATCTTT    1275
CTTCCTGGTGTACAAGCCTTTAAAGACTTCTGCTGCTGATATGCCTCTTGGATGCACACT    1335
TTGTGTGTACATAGTTACCTTTAACTCAGTGGTTATCTAATAGCTCTAAACTCATTAAAA    1395
AAACTCCAAGCCTTCCACCAAAACAGTGCCCCACCTGTATACATTTTTATTAAAAAAATG    1455
TAATGCTTATGTATAAACATGTATGTAATATGCTTTCTATGAATGATGTTTGATTTAAAT    1515
ATAATACATATTAAAATGTATGGGAGAACCAAAAAAAAAAAAAAAAAA                1563
```

## Fig. 2A

```
CCTGTGGGAGAGAGCGCCGGGATCCGGACGGGGTAGCAACCGGGGCAGGCCGTGCCGGCTGA    62
GGAGGTCCTGAGGCTACAGAGCTGCCGCGGCTGGCACACGAGCGCCTCGGCACTAACCGA     122
GTGTTCGCGGGGGCTGTGAGGGGAGGGCCCCGGGCGCCATTGCTGGCGGTGGGAGCGCCG     182
CCCGGTCTCAGCCCGCCCTCGGCTGCTCTCCTCCTCCGGCTGGGAGGGGCCGTATCTCGG     242
GGCCGTCGCCAGCCCCGGCCCGGGCTCGATAATCAAGGGCCTCGGCCGTCGTCCCGCACC     302
TCATTCCATCGCCCTTGCCGGGCAGCCCGGGCAGAGACC ATG TTT GAC AAG ACG       356
                                        Met Phe Asp Lys Thr
                                                          5
CGG CTG CCG TAC GTG GCC CTC GAT GTG CTC TGC GTG TTG CTG GCT       401
Arg Leu Pro Tyr Val Ala Leu Asp Val Leu Cys Val Leu Leu Ala
                 10                  15                  20
TCC ATG CCT ATG GCT GTT CTA AAA TTG GGC CAA ATA TAT CCA TTT       446
Ser Met Pro Met Ala Val Leu Lys Leu Gly Gln Ile Tyr Pro Phe
                 25                  30                  35
CAG AGA GGC TTT TTC TGT AAA GAC AAC AGC ATC AAC TAT CCG TAC       491
Gln Arg Gly Phe Phe Cys Lys Asp Asn Ser Ile Asn Tyr Pro Tyr
                 40                  45                  50
CAT GAC AGT ACC GCC GCA TCC ACT GTC CTC ATC CTA GTG GGG GTT       536
His Asp Ser Thr Ala Ala Ser Thr Val Leu Ile Leu Val Gly Val
                 55                  60                  65
GGC TTG CCC GTT TCC TCT ATT ATT CTT GGA GAA ACC CTG TCT GTT       581
Gly Leu Pro Val Ser Ser Ile Ile Leu Gly Glu Thr Leu Ser Val
                 70                  75                  80
TAC TGT AAC CTT TTG CAC TCA AAT TCC TTT ATC AGT AAT AAC TAC       626
Tyr Cys Asn Leu Leu His Ser Asn Ser Phe Ile Ser Asn Asn Tyr
                 85                  90                  95
ATA GCC ACT ATT TAC AAA GCC ATT GGA ACC TTT TTA TTT GGT GCA       671
Ile Ala Thr Ile Tyr Lys Ala Ile Gly Thr Phe Leu Phe Gly Ala
                100                 105                 110
GCT GCT AGT CAG TCC CTG ACT GAC ATT GCC AAG TAT TCA ATA GGC       716
Ala Ala Ser Gln Ser Leu Thr Asp Ile Ala Lys Tyr Ser Ile Gly
                115                 120                 125
AGA CTG CGG CCT CAC TTC TTG GAT GTT TGT GAT CCA GAT TGG TCA       761
Arg Leu Arg Pro His Phe Leu Asp Val Cys Asp Pro Asp Trp Ser
                130                 135                 140
AAA ATC AAC TGC AGC GAT GGT TAC ATT GAA TAC TAC ATA TGT CGA       806
Lys Ile Asn Cys Ser Asp Gly Tyr Ile Glu Tyr Tyr Ile Cys Arg
                145                 150                 155
GGG AAT GCA GAA AGA GTT AAG GAA GGC AGG TTG TCC TTC TAT TCA       851
Gly Asn Ala Glu Arg Val Lys Glu Gly Arg Leu Ser Phe Tyr Ser
                160                 165                 170
GGC CAC TCT TCG TTT TCC ATG TAC TGC ATG CTG TTT GTG GCA CTT       896
Gly His Ser Ser Phe Ser Met Tyr Cys Met Leu Phe Val Ala Leu
                175                 180                 185
TAT CTT CAA GCC AGG ATG AAG GGA GAC TGG GCA AGA CTC TTA CGC       941
Tyr Leu Gln Ala Arg Met Lys Gly Asp Trp Ala Arg Leu Leu Arg
                190                 195                 200
CCC ACA CTG CAA TTT GGT CTT GTT GCC GTA TCC ATT TAT GTG GGC       986
Pro Thr Leu Gln Phe Gly Leu Val Ala Val Ser Ile Tyr Val Gly
                205                 210                 215
CTT TCT CGA GTT TCT GAT TAT AAA CAC CAC TGG AGC GAT GTG TTG      1031
Leu Ser Arg Val Ser Asp Tyr Lys His His Trp Ser Asp Val Leu
                220                 225                 230
ACT GGA CTC ATT CAG GGA GCT CTG GTT GCA ATA TTA GTT GCT GTA      1076
Thr Gly Leu Ile Gln Gly Ala Leu Val Ala Ile Leu Val Ala Val
                235                 240                 245
```

## *Fig. 2B*

```
TAT GTA TCG GAT TTC TTC AAA GAA AGA ACT TCT TTT AAA GAA AGA     1121
Tyr Val Ser Asp Phe Phe Lys Glu Arg Thr Ser Phe Lys Glu Arg
                250                                     260
AAA GAG GAG GAC TCT CAT ACA ACT CTG CAT GAA ACA CCA ACA ACT     1166
Lys Glu Glu Asp Ser His Thr Thr Leu His Glu Thr Pro Thr Thr
                265                 270                 275
GGG AAT CAC TAT CCG AGC AAT CAC CAG CCT TGA AAGGCAGCAGGGTGCC    1215
Gly Asn His Tyr Pro Ser Asn His Gln Pro ***
                280                 285
CAGGTGAAGCTGGCCTGTTTTCTAAAGGAAAATGATTGCCACAAGGCAAGAGGATGCATC    1275
TTTCTTCCTGGTGTACAAGCCTTTAAAGACTTCTGCTGCTGATATGCCTCTTGGATGCAC    1335
ACTTTGTGTGTACATAGTTACCTTTAACTCAGTGGTTATCTAATAGCTCTAAACTCATTA    1395
AAAAAACTCCAAGCCTTCCACCAAAACAGTGCCCCACCTGTATACATTTTTATTAAAAAA    1455
ATGTAATGCTTATGTATAAACATGTATGTAATATGCTTTCTATGAATGATGTTTGATTTA    1515
AATATAATACATATTAAAATGTATGGGAGAACCAAAAAAAAAAAAAAAAAA            1566
```

## Fig. 3A

```
GGCGCAGCTCTGCAAAAGTTTCTGCTCGGGATCTGGCTCTCTTCCCCTTGGACTTTAGAACG    62
ATTTAGGGTTGACAGAGGAAAGCAGAGGCGCGCAGGAGGAGCAGAAAACACCACCTTCTG    122
CAGTTGGAGGCAGGCAGCCCCGGCTGCACTCTAGCCGCCGCGCCCGGAGCCGGGGCCGAC    182
CCGCCACTATCCGCAGCAGCCTCGGCCAGGAGGCGACCCGGGCGCCTGGGTGTGTGGCTG    242
CTGTTGCGGGACGTCTTCGCGGGGCGGGAGGCTCGCGCCGCAGCCAGCGCC ATG CAA     299
                                                      Met Gln
AAC TAC AAG TAC GAC AAA GCG ATC GTC CCG GAG AGC AAG AAC GGC       344
Asn Tyr Lys Tyr Asp Lys Ala Ile Val Pro Glu Ser Lys Asn Gly
          5                  10                  15
GGC AGC CCG GCG CTC AAC AAC AAC CCG AGG AGG AGC GGC AGC AAG       389
Gly Ser Pro Ala Leu Asn Asn Asn Pro Arg Arg Ser Gly Ser Lys
         20                  25                  30
CGG GTG CTG CTC ATC TGC CTC GAC CTC TTC TGC CTC TTC ATG GCG       434
Arg Val Leu Leu Ile Cys Leu Asp Leu Phe Cys Leu Phe Met Ala
         35                  40                  45
GGC CTC CCC TTC CTC ATC ATC GAG ACA AGC ACC ATC AAG CCT TAC       479
Gly Leu Pro Phe Leu Ile Ile Glu Thr Ser Thr Ile Lys Pro Tyr
         50                  55                  60
CAC CGA GGG TTT TAC TGC AAT GAT GAG AGC ATC AAG TAC CCA CTG       524
His Arg Gly Phe Tyr Cys Asn Asp Glu Ser Ile Lys Tyr Pro Leu
         65                  70                  75
AAA ACT GGT GAG ACA ATA AAT GAC GCT GTG CTC TGT GCC GTG GGG       569
Lys Thr Gly Glu Thr Ile Asn Asp Ala Val Leu Cys Ala Val Gly
         80                  85                  90
ATC GTC ATT GCC ATC CTC GCG ATC ATC ACG GGG GAA TTC TAC CGG       614
Ile Val Ile Ala Ile Leu Ala Ile Ile Thr Gly Glu Phe Tyr Arg
         95                 100                 105
ATC TAT TAC CTG AAG AAG TCG CGG TCG ACG ATT CAG AAC CCC TAC       659
Ile Tyr Tyr Leu Lys Lys Ser Arg Ser Thr Ile Gln Asn Pro Tyr
        110                 115                 120
GTG GCA GCA CTC TAT AAG CAA GTG GGC TGC TTC CTC TTT GGC TGT       704
Val Ala Ala Leu Tyr Lys Gln Val Gly Cys Phe Leu Phe Gly Cys
        125                 130                 135
GCC ATC AGC CAG TCT TTC ACA GAC ATT GCC AAA GTG TCC ATA GGG       749
Ala Ile Ser Gln Ser Phe Thr Asp Ile Ala Lys Val Ser Ile Gly
        140                 135                 150
CGC CTG CGT CCT CAC TTC TTG AGT GTC TGC AAC CCT GAT TTC AGC       794
Arg Leu Arg Pro His Phe Leu Ser Val Cys Asn Pro Asp Phe Ser
        155                 160                 165
CAG ATC AAC TGC TCT GAA GGC TAC ATT CAG AAC TAC AGA TGC AGA       839
Gln Ile Asn Cys Ser Glu Gly Tyr Ile Gln Asn Tyr Arg Cys Arg
        170                                     180
GGT GAT GAC AGC AAA GTC CAG GAA GCC AGG AAG TCC TTC TTC TCT       884
Gly Asp Asp Ser Lys Val Gln Glu Ala Arg Lys Ser Phe Phe Ser
        185                 190                 195
GGC CAT GCC TCC TTC TCC ATG TAC ACT ATG CTG TAT TTG GTG CTA       929
Gly His Ala Ser Phe Ser Met Tyr Thr Met Leu Tyr Leu Val Leu
        200                 205                 210
TAC CTG CAG GCC CGC TTC ACT TGG CGA GGA GCC CGC CTG CTC CGG       974
Tyr Leu Gln Ala Arg Phe Thr Trp Arg Gly Ala Arg Leu Leu Arg
        215                 220                 225
CCC CTC CTG CAG TTC ACC TTG ATC ATG ATG GCC TTC TAC ACG GGA      1019
Pro Leu Leu Gln Phe Thr Leu Ile Met Met Ala Phe Tyr Thr Gly
        230                 235                 240
CTG TCT CGC GTA TCA GAC CAC AAG CAC CAT CCC AGT GAT GTT CTG      1064
Leu Ser Arg Val Ser Asp His Lys His His Pro Ser Asp Val Leu
        245                 250                 255
```

## *Fig. 3B*

```
GCA GGA TTT GCT CAA GGA GCC CTG GTG GCC TGC TGC ATA GTT TTC     1109
Ala Gly Phe Ala Gln Gly Ala Leu Val Ala Cys Cys Ile Val Phe
        260                 265                 270
TTC GTG TCT GAC CTC TTC AAG ACT AAG ACG ACG CTC TCC CTG CCT     1154
Phe Val Ser Asp Leu Phe Lys Thr Lys Thr Thr Leu Ser Leu Pro
        275                 280                 285
GCC CCT GCT ATC CGG AAG GAA ATC CTT TCA CCT GTG GAC ATT ATT     1199
Ala Pro Ala Ile Arg Lys Glu Ile Leu Ser Pro Val Asp Ile Ile
        290                 295                 300
GAC AGG AAC AAT CAC CAC AAC ATG ATG TAG GTGCCACCCACCTCCTGAGC    1249
Asp Arg Asn Asn His His Asn Met Met ***
        305                 310
TGTTTTTGTAAAATGACTGCTGACAGCAAGTTCTTGCTGCTCTCCAATCTCATCAGACAG    1309
TAGAATGTAGGGAAAAACTTTTGCCCGACTGATTTTTAAAAAAAAAAAAAAAA           1362
```

## Fig. 4A

```
ACC ATG CAG CGG AGG TGG GTC TTC GTG CTG CTC GAC GTG CTG TGC      47
    Met Gln Arg Arg Trp Val Phe Val Leu Leu Asp Val Leu Cys
                     5                  10
TTA CTG GTC GCC TCC CTG CCC TTC GCT ATC CTG ACG CTG GTG AAC      92
Leu Leu Val Ala Ser Leu Pro Phe Ala Ile Leu Thr Leu Val Asn
 15                  20                  25
GCC CCG TAC AAG CGA GGA TTT TAC TGC GGG GAT GAC TCC ATC CGG     137
Ala Pro Tyr Lys Arg Gly Phe Tyr Cys Gly Asp Asp Ser Ile Arg
 30                  35                  40
TAC CCC TAC CGT CCA GAT ACC ATC ACC CAC GGG CTC ATG GCT GGG     182
Tyr Pro Tyr Arg Pro Asp Thr Ile Thr His Gly Leu Met Ala Gly
 45                  50                  55
GTC ACC ATC ACG GCC ACC GTC ATC CTT GTC TCG GCC GGG GAA GCC     227
Val Thr Ile Thr Ala Thr Val Ile Leu Val Ser Ala Gly Glu Ala
 60                  65                  70
TAC CTG GTG TAC ACA GAC CGG CTC TAT TCT CGC TCG GAC TTC AAC     272
Tyr Leu Val Tyr Thr Asp Arg Leu Tyr Ser Arg Ser Asp Phe Asn
 75                  80                  85
AAC TAC GTG GCT GCT GTA TAC AAG GTG CTG GGG ACC TTC CTG TTT     317
Asn Tyr Val Ala Ala Val Tyr Lys Val Leu Gly Thr Phe Leu Phe
 90                  95                  100
GGG GCT GCC GTG AGC CAG TCT CTG ACA GAC CTG GCC AAG TAC ATG     362
Gly Ala Ala Val Ser Gln Ser Leu Thr Asp Leu Ala Lys Tyr Met
105                 110                 115
ATT GGG CGT CTG AAG CCC AAC TTC CTA GCC GTC TGC GAC CCC GAC     407
Ile Gly Arg Leu Lys Pro Asn Phe Leu Ala Val Cys Asp Pro Asp
120                 125                 130
TGG AGC CGG GTC AAC TGC TCG GTC TAT GTG CAG CTG GAG AAG GTG     452
Trp Ser Arg Val Asn Cys Ser Val Tyr Val Gln Leu Glu Lys Val
135                 140                 145
TGC AGG GGA AAC CCT GCT GAT GTC ACC GAG GCC AGG TTG TCT TTC     497
Cys Arg Gly Asn Pro Ala Asp Val Thr Glu Ala Arg Leu Ser Phe
150                 155                 160
TAC TCG GGA CAC TCT TCC TTT GGG ATG TAC TGC ATG GTG TTC TTG     542
Tyr Ser Gly His Ser Ser Phe Gly Met Tyr Cys Met Val Phe Leu
165                 170                 175
GCG CTG TAT GTG CAG GCA CGA CTC TGT TGG AAG TGG GCA CGG CTG     587
Ala Leu Tyr Val Gln Ala Arg Leu Cys Trp Lys Trp Ala Arg Leu
180                 185                 190
CTG CGA CCC ACA GTC CAG TTC TTC CTG GTG GCC TTT GCC CTC TAC     632
Leu Arg Pro Thr Val Gln Phe Phe Leu Val Ala Phe Ala Leu Tyr
195                 200                 205
GTG GGC TAC ACC CGC GTG TCT GAT TAC AAA CAC CAC TGG AGC GAT     677
Val Gly Tyr Thr Arg Val Ser Asp Tyr Lys His His Trp Ser Asp
210                 215                 220
GTC CTT GTT GGC CTC CTG CAG GGG GCA CTG GTG GCT GCC CTC ACT     722
Val Leu Val Gly Leu Leu Gln Gly Ala Leu Val Ala Ala Leu Thr
225                 230                 235
GTC TGC TAC ATC TCA GAC TTC TTC AAA GCC CGA CCC CCA CAG CAC     767
Val Cys Tyr Ile Ser Asp Phe Phe Lys Ala Arg Pro Pro Gln His
240                 245                 250
TGT CTG AAG GAG GAG GAG CTG GAA CGG AAG CCC AGC CTG TCA CTG     812
Cys Leu Lys Glu Glu Glu Leu Glu Arg Lys Pro Ser Leu Ser Leu
255                 260                 265
ACG TTG ACC CTG GGG CGA GGC TGA CCACAACCACTTATGGGATACCCGCACT    864
Thr Leu Thr Leu Gly Arg Gly ***
270                 275
```

## Fig. 4B

```
CTTCTTCCTGAGGCCGGACCCCGCCCAGGCAGGGAGCTGCTGTGAGTCCAGCTGATGCCC     924
ACCCAGGTGGTCCCTCCAGCCTGGTTAGGCACTGAGGGTTCTGGACGGGCTCCAGGAACC     984
CTGGGCTGATGGGAGCAGTGAGCGGTTCCGCTGCCCCCTGCCCTGCACTGGACCAGGAGT    1044
CTGGAGATGCCTGGGTAGCCCTCAGCATTTGGAGGGGAACCTGTTCCCGTCGGTCCCCAA    1104
ATATCCCCTTCTTTTTATGGGGTTAAGGAAGGGACCGAGAGATCAGATAGTTGCTGTTTT    1164
GTAAAATGTAATGTATATGTGGTTTTTAGTAAAATAGGGCACCTGTTTCACAAAAAAAAA    1224
AAAAAAAAAA                                                      1234
```

*Fig. 5*



**Fig. 6**



Fig. 7



Fig. 8



*Fig. 9*


PA
PAP
CDS
1,2-DIACYLGLYCEROL (DAG)
CDP--DIACYLGLYCEROL (CDP-DAG)
PC, PE, TG
PI, PG, CL

# INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/07928

A. CLASSIFICATION OF SUBJECT MATTER
IPC(6) :C12N 9/16, 15/55; C12P 13/02, 7/64, 7/62
US CL :536/23.2; 435/196, 128, 134, 135, 147
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.2; 435/196, 128, 134, 135, 147

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|---|---|---|
| Y | KAI, M. et al. Identification and cDNA Cloning of 35-kDa Phosphatidic Acid Phosphatase (Type 2) Bound to Plasma Membranes. The Journal of Biological Chemistry, 02 August 1996. Vol. 271, No. 31, pages 18931-18938. see entire document. | 2, 3, 5, 6, 10-13 |
| Y | Database GENBANK on STN, National Institute of Health, (Bethesda MD), Accession No. AA040858, HILLIER et al., The WashU-Merck EST Project, 30 August 1996. | 2, 3, 5, 6, 10-13 |
| Y | Database GENBANK on STN, National Institute of Health (Bethesda MD), Accession No. H68363, HILLIER et al., The WashU-Merck EST Project, 18 October 1995. | 2, 3, 5, 6, 10-13 |

[X] Further documents are listed in the continuation of Box C. [ ] See patent family annex.

| | | | |
|---|---|---|---|
| * | Special categories of cited documents: | "T" | later document published after the international filing date or priority data and not in conflict with the application but cited to understand the principle or theory underlying the invention |
| "A" | document defining the general state of the art which is not considered to be of particular relevance | "X" | document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone |
| "B" | earlier document published on or after the international filing date | "Y" | document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| "L" | document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | "&" | document member of the same patent family |
| "O" | document referring to an oral disclosure, use, exhibition or other means | | |
| "P" | document published prior to the international filing date but later than the priority date claimed | | |

| Date of the actual completion of the international search | Date of mailing of the international search report |
|---|---|
| 20 MAY 1998 | 30 JUN 1998 |
| Name and mailing address of the ISA/US<br>Commissioner of Patents and Trademarks<br>Box PCT<br>Washington, D.C. 20231<br>Facsimile No. (703) 305-3230 | Authorized officer<br>REBECCA PROUTY<br>Telephone No. (703) 308-0196 |

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/07928

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|---|---|---|
| Y | Database GENBANK on STN, National Institute of Health (Bethesda MD), Accession No. W04968, HILLIER et al., The WashU-Merck EST Project, 23 April 1996. | 2, 3, 5, 6, 10-13 |
| Y | Database GENBANK on STN, National Institute of Health, (Bethesda MD), Accession No. U79294, YU et al., Large Scale Concatenation cDNA Sequencing, 25 March 1997. | 3, 4 |
| Y | BRINDLEY, D.N. Phosphatidate Phosphohydrolase and Signal Transduction. Chemistry and Physics of Lipids. 1996. Vol. 80, pages 45-57, especially pages 47-50. | 13 |

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/07928

B. FIELDS SEARCHED
Electronic data bases consulted (Name of data base and where practicable terms used):

APS, MEDLINE, SCISEARCH, LIFESCI, BIOTECHDS, BIOSIS, EMBASE, CAPLUS, NTIS, WPI
search terms: phosphatidic acid or phosphatidate, phosphatase# or phosphohydrolase#, human or isolat? or purif? or gene# or sequence#

Form PCT/ISA/210 (extra sheet)(July 1992)*